clvs-10q_20160930.htm

0001564590-16-027567.txt : 20161104 0001564590-16-027567.hdr.sgml : 20161104 20161104124653 ACCESSION NUMBER: 0001564590-16-027567 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161104 DATE AS OF CHANGE: 20161104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 161974411 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 10-Q 1 clvs-10q_20160930.htm 10-Q clvs-10q_20160930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2016.

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from to .

Commission file number: 001-35347

Clovis Oncology, Inc.

(Exact name of Registrant as specified in its charter)

Delaware		90-0475355
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
5500 Flatiron Parkway, Suite 100 Boulder, Colorado		80301
(Address of principal executive offices)		(Zip Code)

(303) 625-5000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒		Accelerated filer	☐
Non-accelerated filer	☐	(Do not check if a smaller reporting company)	Smaller reporting company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of October 28, 2016 was 38,585,662.

CLOVIS ONCOLOGY, INC.

FORM 10-Q

TABLE OF CONTENTS

PART I. Financial Information		3

ITEM 1.	Financial Statements (unaudited)	3

	Consolidated Statements of Operations — for the three and nine months ended September 30, 2016 and 2015	3

	Consolidated Statements of Comprehensive Loss — for the three and nine months ended September 30, 2016 and 2015	4

	Consolidated Balance Sheets — as of September 30, 2016 and December 31, 2015	5

	Consolidated Statements of Cash Flows — for the nine months ended September 30, 2016 and 2015	6

	Notes to Unaudited Consolidated Financial Statements	7

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	31

ITEM 4.	Controls and Procedures	31

PART II. Other Information		32

ITEM 1.	Legal Proceedings	32

ITEM 1A.	Risk Factors	34

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	34

ITEM 3.	Defaults Upon Senior Securities	34

ITEM 4.	Mine Safety Disclosures	34

ITEM 5.	Other Information	34

ITEM 6.	Exhibits	35

SIGNATURES		38

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

CLOVIS ONCOLOGY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share amounts)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Revenues:
License and milestone revenue	$	—		$	—		$	—		$	—
Operating expenses:
Research and development		54,338			76,138			196,675			193,256
General and administrative		9,162			8,331			28,541			22,286
Acquired in-process research and development		500			12,000			800			12,000
Impairment of intangible asset		—			—			104,517			—
Change in fair value of contingent purchase consideration		—			783			(24,936	)		2,271
Total expenses		64,000			97,252			305,597			229,813
Operating loss		(64,000	)		(97,252	)		(305,597	)		(229,813	)
Other income (expense):
Interest expense		(2,108	)		(2,099	)		(6,318	)		(6,271	)
Foreign currency gains (losses)		(66	)		(101	)		(434	)		2,004
Other income		252			179			473			252
Other expense, net		(1,922	)		(2,021	)		(6,279	)		(4,015	)
Loss before income taxes		(65,922	)		(99,273	)		(311,876	)		(233,828	)
Income tax benefit		227			628			33,467			508
Net loss	$	(65,695	)	$	(98,645	)	$	(278,409	)	$	(233,320	)
Basic and diluted net loss per common share	$	(1.70	)	$	(2.62	)	$	(7.24	)	$	(6.62	)
Basic and diluted weighted-average common shares outstanding		38,538			37,613			38,429			35,252

See accompanying Notes to Unaudited Consolidated Financial Statements.

CLOVIS ONCOLOGY, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(In thousands)

	Three Months Ended September 30 ,						Nine Months Ended September 30,
	2016			2015			2016			2015
Net loss	$	(65,695	)	$	(98,645	)	$	(278,409	)	$	(233,320	)
Other comprehensive income (loss)
Foreign currency translation adjustments, net of tax		58			416			2,190			(17,186	)
Net unrealized gain (loss) on available-for-sale securities, net of tax		(18	)		7			260			148
Other comprehensive income (loss)		40			423			2,450			(17,038	)
Comprehensive loss	$	(65,655	)	$	(98,222	)	$	(275,959	)	$	(250,358	)

See accompanying Notes to Unaudited Consolidated Financial Statements.

CLOVIS ONCOLOGY, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except for share amounts)

	September 30,			December 31,
	2016			2015
ASSETS
Current assets:
Cash and cash equivalents	$	243,724		$	278,756
Available-for-sale securities		75,054			249,832
Prepaid research and development expenses		7,376			3,377
Other current assets		5,194			7,736
Total current assets		331,348			539,701
Property and equipment, net		4,707			4,946
Intangible assets		—			101,500
Goodwill		60,748			59,327
Other assets		1,821			7,912
Total assets	$	398,624		$	713,386
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	11,076		$	11,260
Accrued research and development expenses		36,088			53,011
Other accrued expenses		11,906			11,305
Total current liabilities		59,070			75,576
Contingent purchase consideration		—			24,661
Deferred income taxes, net		266			31,133
Convertible senior notes		280,813			279,885
Deferred rent, long-term		1,437			1,481
Total liabilities		341,586			412,736
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2016 and December 31, 2015		—			—
Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2016 and December 31, 2015; 38,582,755 and 38,359,454 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively		39			38
Additional paid-in capital		1,162,324			1,129,978
Accumulated other comprehensive loss		(45,010	)		(47,460	)
Accumulated deficit		(1,060,315	)		(781,906	)
Total stockholders' equity		57,038			300,650
Total liabilities and stockholders' equity	$	398,624		$	713,386

See accompanying Notes to Unaudited Consolidated Financial Statements.

CLOVIS ONCOLOGY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	Nine Months Ended September 30,
	2016			2015
Operating activities
Net loss	$	(278,409	)	$	(233,320	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense		29,744			29,458
Depreciation and amortization		819			548
Amortization of premiums and discounts on available-for-sale securities		190			1,319
Amortization of debt issuance costs		928			900
Impairment of intangible asset		104,517			—
Change in fair value of contingent purchase consideration		(24,661	)		(32	)
Loss on disposal of property and equipment		105			—
Deferred income taxes		(33,320	)		(529	)
Changes in operating assets and liabilities:
Prepaid and accrued research and development expenses		(14,877	)		21,046
Other operating assets		2,358			(3,500	)
Accounts payable		(322	)		6,124
Other accrued expenses		923			609
Net cash used in operating activities		(212,005	)		(177,377	)
Investing activities
Purchases of property and equipment		(761	)		(1,175	)
Proceeds from sale of property and equipment		65			-
Purchases of available-for-sale securities		—			(392,540	)
Maturities of available-for-sale securities		175,000			—
Sales of available-for-sale securities		—			140,996
Net cash provided by (used in) investing activities		174,304			(252,719	)
Financing activities
Proceeds from the sale of common stock, net of issuance costs		—			298,509
Proceeds from the exercise of stock options and employee stock purchases		2,602			5,027
Net cash provided by financing activities		2,602			303,536
Effect of exchange rate changes on cash and cash equivalents		67			(674	)
Decrease in cash and cash equivalents		(35,032	)		(127,234	)
Cash and cash equivalents at beginning of period		278,756			482,677
Cash and cash equivalents at end of period	$	243,724		$	355,443
Supplemental disclosure of cash flow information:
Cash paid for interest	$	7,188		$	7,307

See accompanying Notes to Unaudited Consolidated Financial Statements.

CLOVIS ONCOLOGY, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of Business and Basis of Presentation

Clovis Oncology, Inc. (the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. We have and intend to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities.

Basis of Presentation

All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, except for those discussed in the following footnotes, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2015 for a broader discussion of our business and the opportunities and risks inherent in such business.

Reclassifications

Certain reclassifications have been made to prior year amounts to conform to the current year presentation. These reclassifications had no effect on our previously reported results of operations, financial position or cash flows.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to contingent purchase consideration, the allocation of purchase consideration, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Liquidity

We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of our product candidates and achieving a level of revenues adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash.

We intend to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. Based on our current estimates, we believe that our cash, cash equivalents and available-for-sale securities as of September 30, 2016 will allow us to fund activities through at least the next 12 months.

2. Summary of Significant Accounting Policies

Our significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Form 10-K”).

Recently Issued Accounting Standards

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU No. 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. The guidance also requires the presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. This update is effective for annual periods beginning after December 15, 2016, including interim periods within those annual periods. Early adoption is permitted. Amendments related to the timing of when excess tax benefits are recognized should be applied using a modified retrospective transition method. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. We are currently evaluating our planned method of adoption and the impact the standard may have on our consolidated financial statements and related disclosures.

3. EOS Acquisition

On November 19, 2013, we acquired all of the outstanding common and preferred stock of Ethical Oncology Science, S.p.A. (“EOS”) (now known as Clovis Oncology Italy S.r.l.). We paid $11.8 million in cash and issued $173.7 million of common stock at the acquisition date and are obligated to pay additional future cash payments if certain lucitanib regulatory and sales milestones are achieved. The potential contingent milestone payments range from a zero payment, which assumes lucitanib fails to achieve any of the regulatory milestones, to approximately $193.5 million ($65.0 million and €115.0 million) if all regulatory and sales milestones are met, utilizing the translation rate at September 30, 2016.

During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer (see Note 4). At September 30, 2016, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets was zero due to the uncertainty of achieving any of the lucitanib regulatory milestones. At December 31, 2015, the liability for the estimated fair value of the payments recorded on the Consolidated Balance Sheets was $24.7 million.

4. Financial Instruments and Fair Value Measurements

Cash, Cash Equivalents and Available-for-Sale Securities

We consider all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations.

Marketable securities are considered to be available-for-sale securities and consist of U.S. Treasury securities. Available-for-sale securities are reported at fair value on the Consolidated Balance Sheets and unrealized gains and losses are included in accumulated other comprehensive income (loss) on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense) on the Consolidated Statements of Operations. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on our intent to fund current operations with these securities or to make them available for current operations.

A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.

Fair Value Measurements

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The three levels of inputs that may be used to measure fair value include:

Level 1:

Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.


Level 2:		Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

Level 3:		Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets that are measured at fair value on a recurring basis. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired with the purchase of EOS is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. See Note 3 of our 2015 Form 10-K for further discussion of the unobservable inputs and valuation techniques related to the contingent purchase consideration liability.

The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):

	Balance		Level 1		Level 2		Level 3
September 30, 2016
Assets:
Money market	$	227,182	$	227,182	$	—	$	—
U.S. treasury securities		75,054		—		75,054		—
Total assets at fair value	$	302,236	$	227,182	$	75,054	$	—
Liabilities:
Contingent purchase consideration	$	—	$	—	$	—	$	—
Total liabilities at fair value	$	—	$	—	$	—	$	—
December 31, 2015
Assets:
Money market	$	251,037	$	251,037	$	—	$	—
U.S. treasury securities		249,832		—		249,832		—
Total assets at fair value	$	500,869	$	251,037	$	249,832	$	—
Liabilities:
Contingent purchase consideration	$	24,661	$	—	$	—	$	24,661
Total liabilities at fair value	$	24,661	$	—	$	—	$	24,661

There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the nine months ended September 30, 2016.

The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) (in thousands):

	For the Nine
	Months Ended
	September 30, 2016
Liabilities:
Balance at beginning of period	$	24,661
Change in fair value (a)		(24,936	)
Change in foreign currency gains and losses		275
Balance at end of period	$	—

(a)

During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At September 30, 2016, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets was zero due to the uncertainty of achieving any of the lucitanib regulatory milestones.

The change in the fair value of Level 3 instruments is included in change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations.

Assets measured at fair value on a nonrecurring basis include our in-process research and development (“IPR&D”) intangible assets, which were recorded as part of the acquisition of EOS (see Note 3 and Note 7). The fair value of the IPR&D intangible assets was established based upon discounted cash flow models using assumptions related to the timing of development, probability of development and regulatory success, sales and commercialization factors and estimated product life. As the valuation is based on significant unobservable inputs, the fair value measurement is classified as Level 3. IPR&D assets are evaluated for impairment at least annually or more frequently if impairment indicators exist.

During the second quarter of 2016, we recorded a $104.5 million impairment charge due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At September 30, 2016, the IPR&D intangible asset recorded on the Consolidated Balance Sheets was zero.

Financial instruments not recorded at fair value include our convertible senior notes. At September 30, 2016, the carrying amount of the convertible senior notes was $287.5 million, which represents the aggregate principal amount, and the fair value was $273.8 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 9 for discussion of the convertible senior notes.

5. Available-for-Sale Securities

As of September 30, 2016, available-for-sale securities consisted of the following (in thousands):

			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	75,024	$	30	$	—	$	75,054

As of December 31, 2015, available-for-sale securities consisted of the following (in thousands):

			Gross		Gross			Aggregate
	Amortized		Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Value
U.S. treasury securities	$	250,215	$	—	$	(383	)	$	249,832

As of September 30, 2016, there were no available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months.

As of December 31, 2015, the fair value and gross unrealized losses of available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months were as follows (in thousands):

	Aggregate		Gross
	Fair		Unrealized
	Value		Losses
U.S. treasury securities	$	249,832	$	(383	)

As of September 30, 2016, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):

	Amortized		Fair
	Cost		Value
Due in one year or less	$	75,024	$	75,054
Total	$	75,024	$	75,054

6. Other Current Assets

Other current assets were comprised of the following (in thousands):

	September 30,		December 31,
	2016		2015
Receivable from partners	$	1,258	$	3,241
Prepaid expenses- other		2,613		1,023
Receivable - other		825		889
Prepaid insurance		406		1,231
Receivable from landlord		—		1,153
Other		92		199
Total	$	5,194	$	7,736

7. Intangible Assets and Goodwill

IPR&D intangible assets and goodwill were established as part of the purchase accounting of EOS (see Note 3) and consisted of the following (in thousands):

	September 30,			December 31,
	2016			2015
IPR&D intangible assets:
Balance at beginning of period	$	101,500		$	212,900
Impairment of intangible asset (a)		(104,517	)		(89,557	)
Change in foreign currency gains (losses)		3,017			(21,843	)
Balance at end of period	$	—		$	101,500

Goodwill:
Balance at beginning of period	$	59,327		$	66,055
Change in foreign currency gains (losses)		1,421			(6,728	)
Balance at end of period	$	60,748		$	59,327

(a)

During the fourth quarter of 2015, we recorded an $89.6 million impairment charge due to our and our development partner’s decision to discontinue the development of lucitanib for lung cancer, as well as updates to the probability-weighted discounted cash flow assumptions for the breast cancer indication.

IPR&D intangible assets are evaluated for impairment at least annually in the fourth quarter or more frequently if impairment indicators exist and any reduction in fair value is recorded as impairment of intangible asset on the Consolidated Statements of Operations.

As part of the acquisition of EOS, we recorded a deferred tax liability to recognize the difference between the book and tax basis of the assets and liabilities acquired. During the first quarter of 2016, we updated the annual effective tax rate to reflect a reduction in the statutory rate of the foreign jurisdiction, resulting in the recognition of a $3.6 million income tax benefit.

During the second quarter of 2016, we recognized a $29.2 million deferred tax benefit associated with the impairment of the IPR&D intangible asset.

8. Other Accrued Expenses

Other accrued expenses were comprised of the following (in thousands):

	September 30,		December 31,
	2016		2015
Accrued personnel costs	$	10,345	$	8,250
Accrued interest payable		299		2,096
Accrued expenses - other		1,262		959
Total	$	11,906	$	11,305

9. Convertible Senior Notes

On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “Notes”) resulting in net proceeds of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year. The Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.

Holders may convert all or any portion of the Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the Notes, holders may require us to repurchase for cash all or any portion of the Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

In connection with the issuance of the Notes, we incurred $9.2 million of debt issuance costs. The debt issuance costs are presented as a deduction from convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the Notes. As of September 30, 2016 and December 31, 2015, the balance of unamortized debt issuance costs was $6.7 million and $7.6 million, respectively.

The following table sets forth total interest expense recognized related to the Notes during the three and nine months ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Contractual interest expense	$	1,797	$	1,797	$	5,390	$	5,371
Amortization of debt issuance costs		311		302		928		900
Total interest expense	$	2,108	$	2,099	$	6,318	$	6,271

10. Stockholders’ Equity

Accumulated Other Comprehensive Income (Loss)

Accumulated other comprehensive income (loss) consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities.

The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):

							Total
	Foreign						Accumulated
	Currency			Unrealized			Other
	Translation			Gains			Comprehensive
	Adjustments			(Losses)			Income (Loss)
Balance December 31, 2014	$	(24,448	)	$	—		$	(24,448	)
Period change		(22,629	)		(383	)		(23,012	)
Balance December 31, 2015		(47,077	)		(383	)		(47,460	)
Period change		3,526			412			3,938
Income tax expense		(1,335	)		(153	)		(1,488	)
Balance September 30, 2016	$	(44,886	)	$	(124	)	$	(45,010	)

The period change between September 30, 2016 and December 31, 2015 was primarily due to the currency translation of the IPR&D intangible assets, goodwill and deferred income taxes associated with the acquisition of EOS (see Note 3 and Note 7).

11. Share-Based Compensation

Share-based compensation expense for all equity based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and nine months ended September 30, 2016 and 2015 was recognized in the accompanying Consolidated Statements of Operations as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Research and development	$	7,039	$	9,039	$	20,962	$	19,798
General and administrative		2,164		3,367		8,782		9,660
Total share-based compensation expense	$	9,203	$	12,406	$	29,744	$	29,458

We did not recognize a tax benefit related to share-based compensation expense during the three and nine months ended September 30, 2016 and 2015, respectively, as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of September 30, 2016.

The following table summarizes the activity relating to our options to purchase common stock for the nine months ended September 30, 2016:

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value (Thousands)
Outstanding at December 31, 2015		5,360,257		$	51.53
Granted		1,829,537			21.85
Exercised		(139,396	)		7.85
Forfeited		(1,309,127	)		54.27
Outstanding at September 30, 2016 (a)		5,741,271		$	42.51		7.4	$	52,392
Vested and expected to vest at September 30, 2016		5,351,476		$	42.80		7.2	$	48,604
Exercisable at September 30, 2016		2,954,077		$	43.14		5.8	$	27,713

(a)

Includes 42,500 performance-based stock options granted to our executives in the first quarter of 2015, which vest contingent on approval by the U.S. Food and Drug Administration (“FDA”) to commercially distribute, sell or market rucaparib. Stock compensation expense will be recognized when the condition for vesting is probable of being met.

The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $36.05 as of September 30, 2016, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.

The following table summarizes information about our stock options as of and for the three and nine months ended September 30, 2016 and 2015:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Weighted-average grant date fair value per share	$	17.09	$	56.22	$	16.07	$	52.98
Intrinsic value of options exercised	$	930,417	$	5,307,365	$	1,555,342	$	15,361,206
Cash received from stock option exercises	$	687,332	$	1,953,938	$	1,094,855	$	4,534,288

As of September 30, 2016, the unrecognized share-based compensation expense related to unvested options, adjusted for expected forfeitures, was $83.7 million and the estimated weighted-average remaining vesting period was 2.8 years.

During 2016, we issued restricted stock units (“RSUs”) to certain employees under the 2011 Stock Incentive Plan. The RSUs vest over either a two-year period or over a four-year period and are payable in shares of our common stock at the end of the vesting period. RSUs are measured based on the fair value of the underlying stock on the grant date. Shares issued on the vesting dates are net of the minimum statutory tax to be paid by us on behalf of our employees. As a result, the actual number of shares issued will be lower than the actual number of RSUs vested.

The following table summarizes the activity relating to our unvested RSUs for the nine months ended September 30, 2016:

	Number of Units			Weighted- Average Grant Date Fair Value
Unvested as of December 31, 2015		—		$	—
Granted		526,180			21.65
Vested (a)		(9,750	)		19.37
Forfeited		(33,245	)		19.24
Unvested as of September 30, 2016		483,185		$	21.86
Expected to vest after September 30, 2016		398,525		$	21.80

(a)

During the second quarter of 2016, we accelerated the vesting of RSUs for certain employees.

As of September 30, 2016, the unrecognized share-based compensation expense related to unvested RSUs, adjusted for expected forfeitures, was $8.4 million and the estimated weighted-average remaining vesting period was 3.4 years.

12. License Agreements

Rucaparib

In June 2011, we entered into a worldwide license agreement with Pfizer, Inc. to acquire exclusive development and commercialization rights to rucaparib. This drug candidate is a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP), which we are developing for the treatment of selected solid tumors. Under the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer. In April 2014, we initiated a pivotal registration study for rucaparib, which resulted in a $0.4 million milestone payment to Pfizer as required by the license agreement. In September 2016, we made a milestone payment of $0.5 million to Pfizer upon acceptance of the NDA for rucaparib by the FDA. These payments were recognized as acquired in-process research and development expense.

We are responsible for all development and commercialization costs of rucaparib. When and if commercial sales of rucaparib begin, we will pay Pfizer tiered royalties on our net sales. In addition, Pfizer is eligible to receive up to $264.5 million of further payments, in aggregate, if certain development, regulatory and sales milestones are achieved, including $21.25 million associated with the first filing and approval of a New Drug Application (“NDA”) by the FDA. During the second quarter of 2016, we completed the submission of our NDA with the FDA for potential accelerated approval of rucaparib in the U.S. The FDA granted the rucaparib NDA priority review status with a Prescription Drug User Fee Act action date of February 23, 2017. During the fourth quarter of 2016, we submitted a Marketing Authorization Application (“MAA”) for rucaparib to the European Medicines Agency (“EMA”).

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1^st Indication in US and (ii) EMA approval of an MAA for 1^st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones.

Lucitanib

In connection with its acquisition of EOS (see Note 3), we gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Les Laboratoires Servier (“Servier”) in exchange for upfront milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments.

In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen royalties on net sales of lucitanib based on the volume of annual net sales achieved. In addition, we are obligated to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. In the first quarter of 2014, we recognized acquired in-process research and development expense of $3.4 million, which represents 25% of the sublicense agreement consideration of $13.6 million received from Servier upon the end of opposition and appeal of the lucitanib patent by the European Patent Office.

In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an upfront payment of €45.0 million and is entitled to receive additional payments upon achievement of specified development, regulatory and commercial milestones up to €90.0 million in the aggregate. In addition, we are entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, which, in the aggregate, could total €250.0 million. We are also entitled to receive royalties on sales of lucitanib by Servier.

The development, regulatory and commercial milestones represent non-refundable amounts that would be paid by Servier to us if certain milestones are achieved in the future. These milestones, if achieved, are substantive as they relate solely to past performance, are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of our performance, which are reasonable relative to the other deliverables and terms of the arrangement, and are unrelated to the delivery of any further elements under the arrangement.

We and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for all of the initial global development costs under the agreed upon plan up to €80.0 million. Cumulative global development costs, if any, in excess of €80.0 million will be shared equally between us and Servier. During the second quarter of 2016, we and Servier agreed to discontinue the development of lucitanib for breast cancer and are continuing to evaluate, what, if any, further development of lucitanib will be pursued. Based on current estimates, we expect to complete the committed on-going development activities in 2017 and expect full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations.

We recorded a $1.3 million and $3.2 million receivable at September 30, 2016 and December 31, 2015, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. For the three months ending September 30, 2016 and 2015, we incurred $1.3 million and $3.8 million, respectively, in research and development costs and recorded reductions in research and development expense of $1.3 million and $3.8 million, respectively, for reimbursable development costs due from Servier. For the nine months ending September 30, 2016 and 2015, respectively, we incurred $7.4 million and $11.7 million, respectively, in research and development costs and recorded reductions in research and development expense of $7.7 million and $10.4 million, respectively, for reimbursable development costs due from Servier.

Rociletinib

In May 2010, we entered into an exclusive worldwide license agreement with Avila Therapeutics, Inc. (now Celgene Avilomics Research, Inc., part of Celgene Corporation (“Celgene”)) to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor gene product. Rociletinib was identified as the lead inhibitor candidate under the license agreement. We are responsible for all non-clinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib.

We made an upfront payment of $2.0 million upon execution of the license agreement, a $4.0 million milestone payment in the first quarter of 2012 upon acceptance by the FDA of our Investigational New Drug application for rociletinib and a $5.0 million milestone payment in the first quarter of 2014 upon initiation of the Phase II study for rociletinib. In the third quarter of 2015, we made milestone payments totaling $12.0 million upon acceptance of the NDA and MAA for rociletinib by the FDA and EMA, respectively. We recognized all payments as acquired in-process research and development expense.

During the second quarter of 2016, we received a Complete Response Letter (“CRL”) from the FDA for the rociletinib NDA. The FDA issues a CRL to indicate that their review of an application is complete and that the application is not ready for approval. In anticipation of receiving the CRL, we terminated enrollment in all ongoing sponsored clinical studies, although we continue to provide drug to patients whose clinicians recommend continuing rociletinib therapy. In addition, we withdrew our MAA for rociletinib on file with the EMA. We are continuing analyses of rociletinib data to determine whether certain populations of patients may represent an opportunity for a partner committed to investing in further clinical development.

We are obligated to pay royalties on net sales of rociletinib based on the volume of annual net sales achieved. We are required to pay up to an additional aggregate of $98.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are required to pay up to an aggregate of $120.0 million in sales milestone payments if certain annual sales targets are achieved.

13. Net Loss Per Common Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):

	Three and Nine Months Ended September 30,
	2016		2015
Convertible senior notes		4,646		4,646
Common shares under options and awards		3,772		5,232
Total potential dilutive shares		8,418		9,878

14. Commitments and Contingencies

Royalty and License Fee Commitments

We have entered into certain license agreements, as identified in Note 12, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. Our payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, no amounts have been recorded on our Consolidated Balance Sheets at September 30, 2016 and December 31, 2015.

Development and Manufacturing Agreement Commitments

In February 2013, we entered into a development and manufacturing agreement with a third-party supplier for the production of the active ingredient for rucaparib. Under the Development and Manufacturing Agreement, we will provide the third-party supplier a rolling 24-month forecast that will be updated by us on a quarterly basis. We are obligated to order the quantity specified in the first 12 months of any forecast. Currently, $48.5 million of purchase commitments exist under this agreement.

Legal Proceedings

The Company and certain of its officers and directors were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition.

On November 19, 2015, Steve Kimbro, a purported shareholder of Clovis, filed a purported class action complaint (the “Kimbro Complaint”) against Clovis and certain of its officers in the United States District Court for the District of Colorado. The Kimbro Complaint purports to be asserted on behalf of a class of persons who purchased Clovis stock between October 31, 2013 and November 15, 2015. The Kimbro Complaint generally alleges that Clovis and certain of its officers violated federal securities laws by making allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib. The Kimbro Complaint seeks unspecified damages.

Also on November 19, 2015, a second purported shareholder class action complaint was filed by Sonny P. Medina, another purported Clovis shareholder, containing similar allegations to those set forth in the Kimbro Complaint, also in the United States District Court for the District of Colorado (the “Medina Complaint”). The Medina Complaint purports to be asserted on behalf of a class of persons who purchased Clovis stock between May 20, 2014 and November 13, 2015. On November 20, 2015, a third complaint was filed by John Moran in the United States District Court for the Northern District of California (the “Moran Complaint”). The Moran Complaint contains similar allegations to those asserted in the Kimbro and Medina Complaints and purports to be asserted on behalf of a plaintiff class who purchased Clovis stock between October 31, 2013 and November 13, 2015.

On December 14, 2015, Ralph P. Rocco, a fourth purported shareholder of Clovis, filed a complaint in the United States District Court for the District of Colorado (the “Rocco Complaint”). The Rocco Complaint contains similar allegations to those set forth in the previous complaints and purports to be asserted on behalf of a plaintiff class who purchased Clovis stock between October 31, 2013 and November 15, 2015.

On January 19, 2016, a number of motions were filed in both the District of Colorado and the Northern District of California seeking to consolidate the shareholder class actions into one matter and for appointment of a lead plaintiff. All lead plaintiff movants other than M. Arkin (1999) LTD and Arkin Communications LTD (the “Arkin Plaintiffs”) subsequently filed notices of non-opposition to the Arkin Plaintiffs’ application.

On February 2, 2016, the Arkin Plaintiffs filed a motion to transfer the Moran Complaint to the District of Colorado (the “Motion to Transfer”). Also on February 2, 2016, the defendants filed a statement in the Northern District of California supporting the consolidation of all actions in a single court, the District of Colorado. On February 3, 2016, the Northern District of California court denied without prejudice the lead plaintiff motions filed in that court pending a decision on the Motion to Transfer.

On February 16, 2016, the defendants filed a memorandum in support of the Motion to Transfer, and plaintiff Moran filed a notice of non-opposition to the Motion to Transfer. On February 17, 2016, the Northern District of California court granted the Motion to Transfer.

On February 18, 2016, the Medina court issued an opinion and order addressing the various motions for consolidation and appointment of lead plaintiff and lead counsel in the District of Colorado actions. By this ruling, the court consolidated the Medina, Kimbro and Rocco actions into a single proceeding. The court also appointed the Arkin Plaintiffs as the lead plaintiffs and Bernstein Litowitz Berger & Grossman as lead counsel for the putative class.

On April 1, 2016, the Arkin Plaintiffs and the defendants filed a stipulated motion to set the schedule for the filing of a consolidated complaint in the Medina, Kimbro and Rocco actions (the “Consolidated Complaint”) and the responses thereto, including the defendants’ motion to dismiss the Consolidated Complaint (the “Motion to Dismiss”), and to stay discovery and related proceedings until the District of Colorado issues a decision on the Motion to Dismiss. The stipulated motion was entered by the District of Colorado on April 4, 2016. Subject to further agreed-upon extensions by the parties, the Arkin Plaintiffs filed a Consolidated Complaint on May 6, 2016.

The Consolidated Complaint names as defendants the Company and certain of its current and former officers (the “Clovis Defendants”), certain underwriters (the “Underwriter Defendants”) for a Company follow-on offering conducted in July 2015 (the “July 2015 Offering”) and certain Company venture capital investors (the “Venture Capital Defendants”). The Consolidated Complaint alleges that defendants violated particular sections of the Securities Exchange Act of 1934 (the “Exchange Act”) and the Securities Act of 1933 (the “Securities Act”). The purported misrepresentations and omissions concern allegedly misleading statements about rociletinib. The putative class action is purportedly brought on behalf of investors who purchased the Company’s securities between May 31, 2014 and April 7, 2016 (with respect to the Exchange Act claims) and investors who purchased the Company’s securities pursuant or traceable to the July 2015 Offering (with respect to the Securities Act claims). The Consolidated Complaint seeks unspecified compensatory and recessionary damages.

On May 23, 2016, the Medina, Kimbro, Rocco and Moran actions were consolidated for all purposes in a single proceeding in the District of Colorado.

The Clovis Defendants, along with the Underwriter Defendants and the Venture Capital Defendants, filed a Motion to Dismiss on July 27, 2016, the Arkin Plaintiffs filed their opposition on September 23, 2016, and the defendants filed their replies on October 14, 2016.

The Clovis Defendants intend to vigorously defend against the allegations contained in the Kimbro, Medina, Moran and Rocco Complaints, but there can be no assurance that the defense will be successful.

On December 30, 2015, Jamie McCall, a purported shareholder of Clovis, filed a shareholder derivative complaint (the “McCall Complaint”) against certain officers and directors of Clovis in the Colorado District Court, County of Boulder. The McCall Complaint generally alleged that the defendants breached their fiduciary duties owed to Clovis by participating in misrepresentation of the Company’s business operations and prospects. The McCall Complaint also alleged claims for abuse of control, gross mismanagement and unjust enrichment. The McCall Complaint sought, among other things, an award of money damages, declaratory and injunctive relief concerning the alleged fiduciary breaches and other forms of equitable relief. On March 17, 2016, the plaintiff filed a notice of voluntary dismissal of the McCall Complaint and the action was terminated by the Court.

On January 22, 2016, the Electrical Workers Local #357 Pension and Health & Welfare Trusts, a purported shareholder of Clovis, filed a purported class action complaint (the “Electrical Workers Complaint”) against Clovis and certain of its officers, directors, investors and underwriters in the Superior Court of the State of California, County of San Mateo. The Electrical Workers Complaint purports to be asserted on behalf of a class of persons who purchased stock in Clovis’ July 8, 2015 follow-on offering. The Electrical Workers Complaint generally alleges that the defendants violated the Securities Act because the offering documents for the July 8, 2015 follow-on offering contained allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib. The Electrical Workers Complaint seeks unspecified damages.

On February 25, 2016, the defendants removed the case to the United States District Court for the Northern District of California and thereafter moved to transfer the case to the District of Colorado (“Motion to Transfer”). On March 2, 2016, the plaintiff filed a motion to remand the case to San Mateo County Superior Court (“Motion to Remand”). Following briefing on the Motion to Transfer and the Motion to Remand, the Northern District of California held a hearing on April 18, 2016 concerning the Motion to Remand, at the conclusion of which the court granted to the Motion to Remand. On May 5, 2016, the Northern District of California issued a written decision and order granting the Motion to Remand the case to the Superior Court, County of San Mateo and denying the Motion to Transfer as moot.

While the case was pending in the United States District Court for the Northern District of California, the parties entered into a stipulation extending the defendants’ time to respond to the Electrical Workers Complaint for 30 days following the filing of an amended complaint by plaintiff or the designation by plaintiff of the Electrical Workers Complaint as the operative complaint. Following remand, Superior Court of the State of California, County of San Mateo so-ordered the stipulation on June 22, 2016.

On June 30, 2016, the Electrical Workers Plaintiffs filed an amended Complaint (the “Amended Complaint”). The Amended Complaint names as defendants the Company and certain of its current and former officers and directors, certain underwriters for the July 2015 Offering and certain Company venture capital investors. The Amended Complaint purports to assert claims under the Securities Act based upon alleged misstatements in Clovis’ offering documents for the July 2015 Offering. The Amended Complaint includes new allegations about the Company’s rociletinib disclosures. The Amended Complaint seeks unspecified damages.

Pursuant to a briefing schedule ordered by the court on July 28, 2016, defendants filed a motion to stay the Electrical Workers action pending resolution of the Medina, Kimbro, Moran, and Rocco actions in the District of Colorado (“Motion to Stay”), and a demurrer to the Amended Complaint, on August 15, 2016; plaintiffs filed their oppositions on August 31, 2016; and the defendants filed their reply briefs on September 15, 2016. On September 23, 2016, after hearing oral argument, the San Mateo Superior Court granted defendants’ motion to stay proceedings pending resolution of the related securities class action captioned Medina v. Clovis Oncology, Inc., et. al., No. 1:15-cv-2546 (the “Colorado Action”). Per the order to stay proceedings, the San Mateo Superior Court will defer issuing a ruling on defendants’ pending demurrer, and the parties’ first status report as to the progress of the Colorado Action is due on March 23, 2017.

The Company intends to vigorously defend against the allegations contained in the Electrical Workers Amended Complaint, but there can be no assurance that the defense will be successful.

On February 19, 2016, Maris Sanchez, a purported shareholder of Clovis, filed a shareholder derivative complaint (the “Sanchez Complaint”) against certain officers and directors of Clovis in the United States District Court for the District of Colorado. The Sanchez Complaint generally alleged that the defendants breached their fiduciary duties owed to Clovis by participating in misrepresentation of the Company’s business operations and prospects. The Sanchez Complaint also alleged claims for abuse of control and gross mismanagement. The Sanchez Complaint sought, among other things, an award of money damages. On March 11, 2016, the plaintiff filed a notice of voluntary dismissal of the Sanchez Complaint without prejudice. On March 14, 2016, the Sanchez action was terminated by the District of Colorado.

We have received requests for information from governmental agencies relating to our regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. We are cooperating with the inquiries.

We received a letter dated May 31, 2016 from an alleged owner of our common stock, which purports to set forth a demand for inspection of certain of our books and records pursuant to 8 Del. C. § 220 (the “Demand Letter”). The Demand Letter was purportedly made for the purpose of investigating alleged misconduct at the Company relating to rociletinib. On June 24, 2016, we submitted a response to the Demand Letter. We believe that the Demand Letter fails to establish an entitlement to any of the requested documents, but there can be no assurance about the likelihood of an adverse outcome.

15. Subsequent Events

On October 3, 2016, we entered into a Manufacturing Services Agreement (the “Agreement”) with Lonza Ltd (“Lonza”) for the long term manufacture and supply of the active pharmaceutical ingredient (“API”) for rucaparib. The terms and conditions of the Agreement are contingent upon the approval by the FDA of the initial NDA for rucaparib, unless triggered earlier by us. Clovis and Lonza are parties to a Development and Manufacturing Agreement, dated February 8, 2013, as amended, under which Lonza has supplied rucaparib API for clinical development.

The Agreement provides that Lonza will be a non-exclusive manufacturer of the rucaparib API during the term of the Agreement, which expires on December 31, 2025, unless extended by mutual written consent of the parties. Under the Agreement, Lonza will construct, in an existing Lonza facility, a production train that will be exclusively dedicated to the manufacture of the rucaparib API. The dedicated production train will provide manufacturing capacity to meet our currently anticipated needs for commercial supply of rucaparib API.

We are obligated to make scheduled capital program fee payments towards capital equipment and other costs associated with the construction of the dedicated production train and, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement.

Pursuant to the terms of the Agreement, Lonza will manufacture and store an advanced intermediate to be used in the subsequent production of the rucaparib API. We will pay fixed fees on a per kilogram basis for quantities of the advanced intermediate and the rucaparib API ordered by us under the Agreement, subject to certain adjustments. Until the dedicated facility is completed and operationally qualified, Lonza will manufacture the rucaparib API in existing Lonza facilities at pricing established in the Agreement.

Either party may terminate the Agreement due to a material breach of the Agreement by the other party, subject to prior written notice and a cure period. We may terminate the Agreement, subject to 90 days’ prior written notice, in the event rucaparib is withdrawn from the market for certain reasons. In the event of such a termination by us, or termination by Lonza due to material breach by us, we are obligated to compensate Lonza for any services rendered, or for which costs have been incurred by Lonza in anticipation of services to be provided to us, and to pay to Lonza the remaining amount of any capital program fees and quarterly fixed facility fees for the remainder of the term of the Agreement. In the event the Agreement is terminated by us due to material breach by Lonza, Lonza is obligated to repay all or a portion of the capital program fees previously paid by us.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Information

This Quarterly Report on Form 10-Q and the information incorporated herein by reference includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned non-clinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein.

Any forward-looking statements that we make in this Quarterly Report on Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

You should also read carefully the factors described in the “Risk Factors” section of this Quarterly Report on Form 10-Q to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. You are advised, however, to consult any further disclosures we make on related subjects in our other reports filed with the SEC and on our website.

Overview

We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use.

Our lead product candidate under active development is rucaparib, which is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) currently in advanced clinical development for the treatment of ovarian cancer. During the second quarter of 2016, we completed the submission of our New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for potential accelerated approval of rucaparib in the U.S. We submitted our first E.U. regulatory application in the fourth quarter of 2016. The FDA granted the rucaparib NDA priority review status with a Prescription Drug User Fee Act action date of February 23, 2017. We hold global development and commercialization rights for rucaparib.

In addition, we have two other product candidates: lucitanib and rociletinib. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Lucitanib was previously evaluated in breast and lung cancers. Development in those indications has ceased and we continue to provide drug to patients whose clinicians recommend continuing lucitanib therapy. Along with our development partner, Servier, we are continuing to evaluate development options for lucitanib. We hold development and commercialization rights in the U.S. and Japan and have sublicensed rights to Europe and rest of world markets, excluding China, to Servier.

Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (“EGFR”). During the second quarter of 2016, we received a Complete Response Letter (“CRL”) from the FDA for the rociletinib NDA, which was submitted during the third quarter of 2015. The FDA issues a CRL to indicate that their review of an application is complete and that the application is not ready for approval. In anticipation of receiving the CRL, we terminated enrollment in all ongoing sponsored clinical studies, although we continue to provide drug to patients whose clinicians recommend continuing rociletinib therapy. In addition, we withdrew our Marketing Authorization Application (“MAA”) for rociletinib on file with the European Medicines Agency (“EMA”). We hold global development and commercialization rights for rociletinib.

To date, we have devoted substantially all of our resources to identifying and in-licensing product candidates, performing development activities with respect to those product candidates and the general and administrative support of these operations. To date, we have generated $13.6 million in license and milestone revenue, but have generated no product revenues. We have principally funded our operations using the net proceeds from the sale of convertible preferred stock, the issuance of convertible promissory notes, public offerings of our common stock and our convertible senior notes offering.

We have never been profitable and, as of September 30, 2016, we had an accumulated deficit of $1,060.3 million. We expect to incur significant losses for the foreseeable future, as we advance our product candidates through clinical development to seek regulatory approval and, if approved, commercialize such product candidates. Based on our current estimates, we believe that our cash, cash equivalents and available-for-sale securities as of September 30, 2016 will allow us to fund activities through at least the next 12 months. We expect to finance future cash needs through a combination of public or private equity or debt offerings, collaborations, strategic alliances or other similar licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.

Product License Agreements

Rucaparib

In June 2011, we entered into a license agreement with Pfizer Inc. to acquire exclusive global development and commercialization rights to rucaparib. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer. In April 2014, we initiated a pivotal registration study for rucaparib, which resulted in a $0.4 million milestone payment to Pfizer as required by the license agreement. In September 2016, we made a milestone payment of $0.5 million to Pfizer upon acceptance of the NDA for rucaparib by the FDA. These payments were recognized as acquired in-process research and development expense.

We are responsible for all development and commercialization costs of rucaparib. When and if commercial sales of rucaparib begin, we will pay Pfizer tiered royalties on our net sales. In addition, Pfizer is eligible to receive up to $264.5 million of further payments, in aggregate, if certain development, regulatory and sales milestones are achieved, including $21.25 million associated with the first filing and approval of an NDA by the FDA. During the second quarter of 2016, we completed the submission of our NDA with the FDA for potential accelerated approval of rucaparib in the U.S. The FDA granted the rucaparib NDA priority review status with a Prescription Drug User Fee Act action date of February 23, 2017. During the fourth quarter of 2016, we submitted an MAA for rucaparib to the EMA.

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) EMA approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones.

Lucitanib

On November 19, 2013, we acquired all of the issued and outstanding capital stock of Ethical Oncology Science, S.p.A. (“EOS”) (now known as Clovis Oncology Italy S.r.l.) and gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for upfront milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments.

In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen royalties on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, we are obligated to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. In the first quarter of 2014, we recognized acquired in-process research and development expense of $3.4 million, which represents 25% of the sublicense agreement consideration of $13.6 million received from Servier upon the end of opposition and appeal of the lucitanib patent by the European Patent Office.

In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an upfront payment of €45.0 million. We are entitled to receive additional payments upon achievement of specified development, regulatory and commercial milestones up to an additional €90.0 million in the aggregate. In addition, we are entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, which, in the aggregate, could total €250.0 million. We are also entitled to receive royalties on net sales of lucitanib by Servier.

We and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for all of the initial global development costs under the agreed upon plan up to €80.0 million. Cumulative global development costs, if any, in excess of €80.0 million will be shared equally between us and Servier. During the second quarter of 2016, we and Servier agreed to discontinue the development of lucitanib for breast cancer and are continuing to evaluate what, if any, further development of lucitanib will be pursued. Based on current estimates, we expect to complete the committed on-going development activities in 2017 and expect full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations.

Rociletinib

In May 2010, we entered into an exclusive worldwide license agreement with Avila Therapeutics, Inc. (now Celgene Avilomics Research, Inc., part of Celgene Corporation (“Celgene”)) to discover, develop and commercialize a covalent inhibitor of mutant forms of the EGFR gene product. Rociletinib was identified as the lead inhibitor candidate under the license agreement. We are responsible for all non-clinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib.

We made an upfront payment of $2.0 million upon execution of the license agreement, a $4.0 million milestone payment in the first quarter of 2012 upon acceptance by the FDA of our Investigational New Drug application for rociletinib and a $5.0 million milestone payment in the first quarter of 2014 upon the initiation of the Phase II study for rociletinib. In the third quarter of 2015, we made milestone payments totaling $12.0 million upon acceptance of the NDA and MAA for rociletinib by the FDA and EMA, respectively. We recognized all payments as acquired in-process research and development expense.

Financial Operations Overview

Revenue

To date, we have generated $13.6 million in license and milestone revenue related to our collaboration and license agreement with Servier. In the future, we may generate revenue from the sales of product candidates that are under development by us, as well as from milestone payments or royalties pursuant to our sublicense agreement with Servier. If we fail to successfully complete the regulatory review and development of our product candidates and, together with our partners, companion diagnostics or obtain regulatory approval for them, our ability to generate future revenue and our results of operations and financial position will be adversely affected.

Research and Development Expenses

Research and development expenses consist of costs incurred for the development of our product candidates and companion diagnostics, which include:

•

license fees and milestone payments related to the acquisition of in-licensed products, which are reported on our Consolidated Statements of Operations as acquired in-process research and development;

•

employee-related expenses, including salaries, benefits, travel and share-based compensation expense;

•

expenses incurred under agreements with contract research organizations and investigative sites that conduct our clinical trials;

•

the cost of acquiring, developing and manufacturing clinical trial materials;

•

costs associated with non-clinical activities and regulatory operations;

•

market research, disease education and other commercial product planning activities, including the hiring of a U.S. sales and marketing and medical affairs organization in preparation for potential commercial launch of rucaparib; and

•

activities associated with the development of companion diagnostics for our product candidates.

Research and development costs are expensed as incurred. License fees and milestone payments related to in-licensed products and technology are expensed if it is determined that they have no alternative future use. Costs for certain development activities, such as clinical trials and manufacturing of clinical supply, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors. We expect research and development expenses in 2016 to decrease compared to 2015.

The following table identifies research and development and acquired in-process research and development costs on a program-specific basis for our products under development. Personnel-related costs, depreciation and share-based compensation are not allocated to specific programs, as they are deployed across multiple projects under development and, as such, are separately classified as personnel and other expenses in the table below.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016			2015
	(in thousands)
Rucaparib Expenses
Research and development	$	25,773	$	14,939	$	74,709		$	38,762
Acquired in-process research and development		500		—		800			—
Rucaparib Total		26,273		14,939		75,509			38,762
Lucitanib Expenses
Research and development (a)		3		37		(211	)		1,280
Lucitanib Total		3		37		(211	)		1,280
Rociletinib Expenses
Research and development		3,040		36,371		40,455			96,365
Acquired in-process research and development		—		12,000		—			12,000
Rociletinib Total		3,040		48,371		40,455			108,365
Personnel and other expenses		25,522		24,791		81,722			56,849
Total	$	54,838	$	88,138	$	197,475		$	205,256

(a)

This amount reflects actual costs incurred less amounts due from Servier for reimbursable development expenses pursuant to the collaboration and license agreement described in Note 12 to our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q.

General and Administrative Expenses

General and administrative expenses consist principally of salaries and related costs for personnel in executive, finance, legal, investor relations, human resources and information technology functions. Other general and administrative expenses include facilities expenses, communication expenses, information technology costs, corporate insurance and professional fees for legal, consulting and accounting services.

Effective May 9, 2016, at Mr. Mahaffy’s request, the Compensation Committee of the Board of Directors approved his waiver of any annual base salary in excess of $1.00, plus the cost of the employee portion of any premiums to be paid pursuant to any health and welfare benefit plans maintained by us and any tax withholdings related to health and welfare benefits. Such waiver shall continue in effect until the earliest to occur of (i) the Company entering into a definitive agreement with respect to a transaction that if consummated would constitute a Change in Control (as defined in his Employment Agreement) or the public announcement of a proposal or transaction that if consummated would constitute a Change of Control, (ii) approval by the FDA to commercially distribute, sell or market rucaparib, and (iii) termination of his employment by the Company without Just Cause or by Mr. Mahaffy for Good Reason (each as defined in his Employment Agreement).

Acquired In-Process Research and Development Expenses

Acquired in-process research and development expenses consist of upfront payments to acquire a new drug compound, as well as subsequent milestone payments. Acquired in-process research and development payments are immediately expensed provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use.

Impairment of Intangible Asset

In connection with the acquisition of EOS, we recorded intangible assets to reflect the fair value of acquired in-process research and development (“IPR&D”) as of the acquisition date. The fair value was established based upon discounted cash flow models using assumptions related to the timing of development, probability of development and regulatory success, sales and commercialization factors and estimated product life. During the second quarter of 2016, we recorded a $104.5 million impairment charge due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At September 30, 2016, the IPR&D intangible asset recorded on the Consolidated Balance Sheets was zero.

The IPR&D intangible assets are treated as indefinite-lived intangible assets and are not amortized. IPR&D intangible assets are evaluated for impairment at least annually or more frequently if impairment indicators exist and any reduction in fair value is recorded as impairment of intangible asset on the Consolidated Statements of Operations.

Change in Fair Value of Contingent Purchase Consideration

In connection with the acquisition of EOS, we also recorded a purchase consideration liability equal to the estimated fair value of future payments that are contingent upon the achievement of various regulatory and sales milestones. Subsequent to the acquisition date, we re-measure contingent consideration arrangements at fair value each reporting period and record changes in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations. Changes in fair value are primarily attributed to new information about the likelihood of achieving such milestones and the passage of time. In the absence of new information, changes in fair value reflect only the passage of time as we progress towards the achievement of future milestones. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At September 30, 2016, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets was zero due to the uncertainty of achieving any of the lucitanib regulatory milestones.

Other Income and Expense

Other income and expense is primarily comprised of foreign currency gains and losses resulting from transactions with contract research organizations, investigational sites and contract manufacturers where payments are made in currencies other than the U.S. dollar. In addition, a significant portion of the contingent purchase consideration liability will be settled in Euro-denominated payments if certain future milestones are achieved and is subject to fluctuations in foreign currency rates. Other expense also includes interest expense recognized related to our convertible senior notes.

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates and judgments, including those related to contingent purchase consideration, the allocation of purchase consideration, intangible asset impairment, clinical trial accruals and share-based compensation. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For a description of our critical accounting policies, please see Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. There have not been any material changes to our critical accounting policies since December 31, 2015.

Recently Issued Accounting Standards

In March 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU No. 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. The guidance also requires the presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. This update is effective for annual periods beginning after December 15, 2016, including interim periods within those annual periods. Early adoption is permitted. Amendments related to the timing of when excess tax benefits are recognized should be applied using a modified retrospective transition method. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. We are currently evaluating our planned method of adoption and the impact the standard may have on our consolidated financial statements and related disclosures.

Results of Operations

Comparison of Three Months Ended September 30, 2016 and 2015:

The following table summarizes the results of our operations for the three months ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,						Change 2016 vs. 2015
	2016			2015			$			%
Operating expenses:
Research and development	$	54,338		$	76,138		$	(21,800	)		(29	%)
General and administrative		9,162			8,331			831			10	%
Acquired in-process research and development		500			12,000			(11,500	)		(96	%)
Change in fair value of contingent purchase consideration		—			783			(783	)		(100	%)
Total expenses		64,000			97,252			(33,252	)		(34	%)
Operating loss		(64,000	)		(97,252	)		33,252			(34	%)
Other income (expense):
Interest expense		(2,108	)		(2,099	)		(9	)		0	%
Foreign currency gains (losses)		(66	)		(101	)		35			(35	%)
Other income		252			179			73			41	%
Other income (expense), net		(1,922	)		(2,021	)		99			(5	%)
Loss before income taxes		(65,922	)		(99,273	)		33,351			(34	%)
Income tax benefit (expense)		227			628			(401	)		(64	%)
Net loss	$	(65,695	)	$	(98,645	)	$	32,950			(33	%)

Research and Development Expenses. Research and development expenses decreased during the three months ended September 30, 2016 compared to the same period in the prior year primarily due to decreased development activities for the rociletinib program, partially offset by higher expenses related to the rucaparib program.

Clinical trial costs for rucaparib were $3.3 million higher than the same quarter in the prior year primarily due to higher enrollment in the ARIEL2 and ARIEL3 studies in ovarian cancer. Market research, disease education and other commercial product planning activities were $3.6 million higher than the same quarter in the prior year due to the preparation for the potential regulatory approval and commercial launch of rucaparib. In addition, clinical supply and related manufacturing development costs were $3.9 million higher than the third quarter of 2015, as we increased production to support the expanded clinical studies.

Clinical trial costs for rociletinib were $15.4 million lower than the third quarter in 2015 primarily due to the completion of patient enrollment for all of the TIGER studies in non-small cell lung cancer. Market research, disease education and other commercial product planning activities were $9.6 million lower than the same quarter in the prior year. We incurred higher costs during the third quarter of 2015 due to the preparation for the potential regulatory approval and commercial launch of rociletinib. In addition, clinical supply and related manufacturing development costs were $6.3 million lower than the third quarter in 2015 driven by timing of production to support our clinical studies.

General and Administrative Expenses. General and administrative expenses increased during the three months ended September 30, 2016 compared to the same period in the prior year primarily due to $2.2 million of higher legal expense, partially offset by $1.2 million lower share-based compensation expense.

Acquired In-Process Research and Development Expenses. Acquired in-process research and development expenses decreased during the three months ended September 30, 2016 compared to the same period in the prior year. During the third quarter of 2015, we made milestone payments totaling $12.0 million to Celgene upon acceptance of the NDA and MAA for rociletinib by the FDA and EMA, respectively. During the third quarter of 2016, we made a milestone payment of $0.5 million to Pfizer upon acceptance of the NDA for rucaparib by the FDA.

Change in Fair Value of Contingent Purchase Consideration. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At September 30, 2016, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets was zero due to the uncertainty of achieving any of the lucitanib regulatory milestones.

Comparison of Nine Months Ended September 30, 2016 and 2015:

The following table summarizes the results of our operations for the nine months ended September30, 2016 and 2015 (in thousands):

	Nine Months Ended September 30,						Change 2016 vs. 2015
	2016			2015			$			%
Operating expenses:
Research and development	$	196,675		$	193,256		$	3,419			2	%
General and administrative		28,541			22,286			6,255			28	%
Acquired in-process research and development		800			12,000			(11,200	)		(93	%)
Impairment of intangible asset		104,517			—			104,517		n/a
Change in fair value of contingent purchase consideration		(24,936	)		2,271			(27,207	)		(1,198	%)
Total expenses		305,597			229,813			75,784			33	%
Operating loss		(305,597	)		(229,813	)		(75,784	)		33	%
Other income (expense):
Interest expense		(6,318	)		(6,271	)		(47	)		1	%
Foreign currency gains (losses)		(434	)		2,004			(2,438	)		(122	%)
Other income		473			252			221			88	%
Other expense, net		(6,279	)		(4,015	)		(2,264	)		56	%
Loss before income taxes		(311,876	)		(233,828	)		(78,048	)		33	%
Income tax benefit (expense)		33,467			508			32,959			6,488	%
Net loss	$	(278,409	)	$	(233,320	)	$	(45,089	)		19	%

Research and Development Expenses. Research and development expenses increased during the nine months ended September 30, 2016 compared to the same period in the prior year primarily due to increased development activities for the rucaparib program and higher salaries, share-based compensation and other personnel-related costs, partially offset by lower expenses related to the rociletinib program.

Clinical trial costs for rucaparib were $13.8 million higher than the same period in the prior year primarily due to higher enrollment in the ARIEL2 and ARIEL3 studies in ovarian cancer. Market research, disease education and other commercial product planning activities were $10.6 million higher than the same period in the prior year due to the preparation for the potential regulatory approval and commercial launch of rucaparib. Clinical supply and related manufacturing development costs were $6.8 million higher than 2015, as we increased production to support the expanded clinical studies. In addition, diagnostic development costs for rucaparib were $3.2 million higher than 2015 due to the advancement of our collaboration with Foundation Medicine, Inc. to develop a novel companion diagnostic test to identify patients most likely to respond to rucaparib.

Salaries, share-based compensation expense and other personnel-related costs were $24.4 million higher in 2016 driven by increased headcount to support our expanded development and commercial planning activities. During the third quarter of 2015, we completed the hiring of our U.S. sales and marketing and medical affairs organizations in preparation for the potential regulatory approval and commercial launch of rucaparib.

Clinical trial costs for rociletinib were $29.1 million lower than 2015 primarily due to the completion of patient enrollment in the TIGER-1, TIGER-2 and TIGER-X studies in non-small cell lung cancer. This decrease was partially offset by higher clinical trial costs for the TIGER-3 study, which began enrolling patients during the second quarter of 2015. Market research, disease education and other commercial product planning activities were $14.2 million lower than the prior year. We incurred higher costs during 2015 due to the preparation for the potential regulatory approval and commercial launch of rociletinib. In addition, clinical supply and related manufacturing development costs were $12.6 million lower than 2015 driven by timing of production to support our clinical studies.

General and Administrative Expenses. General and administrative expenses increased during the nine months ended September 30, 2016 compared to the same period in the prior year primarily due to $5.4 million higher legal expense and $0.8 million higher personnel costs.

Acquired In-Process Research and Development Expenses. Acquired in-process research and development expenses decreased during the nine months ended September 30, 2016 compared to the same period in the prior year. During the third quarter of 2015, we made milestone payments totaling $12.0 million to Celgene upon acceptance of the NDA and MAA for rociletinib by the FDA and EMA, respectively. During the second quarter of 2016, we made a milestone payment of $0.3 million to AstraZeneca upon the NDA submission for rucaparib and during the third quarter of 2016, we made a milestone payment of $0.5 million to Pfizer upon acceptance of the NDA for rucaparib by the FDA.

Impairment of Intangible Asset. During the second quarter of 2016, we recorded a $104.5 million impairment charge to the IPR&D intangible asset relating to our lucitanib product candidate. This reduction in the estimated fair value of lucitanib was the result of our and our development partner’s decision to discontinue the development of lucitanib for breast cancer.

Change in Fair Value of Contingent Purchase Consideration. Change in fair value of contingent purchase consideration totaled ($24.9) million for the nine months ended September 30, 2016 compared to $2.3 million for the same period in the prior year. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer.

Other Income (Expense), net. Other expense increased during the nine months ended September 30, 2016 compared to the same period in the prior year. During the nine months ended September 30, 2016, we recognized $0.4 million of foreign currency losses compared with $2.0 million of foreign currency gains during the same period in 2015. The change in the foreign currency gains and losses was driven by fluctuations in the foreign currency rate utilized to translate our Euro-denominated contingent purchase consideration liability into U.S. dollars.

Income Tax Benefit (Expense). During the nine months ended September 30, 2016, we recognized a $29.2 million deferred tax benefit associated with the impairment of the IPR&D intangible asset recorded in the second quarter of 2016. In addition, during the first quarter of 2016, we recognized a $3.6 million deferred tax benefit due to a reduction in the enacted corporate tax rate of a foreign jurisdiction in which we operate.

Liquidity and Capital Resources

To date, we have funded our operations through the public offering of our common stock and the private placement of convertible debt securities and preferred stock. At September 30, 2016, we had cash, cash equivalents and available-for-sale securities totaling $318.8 million.

The following table sets forth the primary sources and uses of cash for the nine months ended September 30, 2016 and 2015:

	Nine Months Ended September 30,
	2016			2015
	(in thousands)
Net cash used in operating activities	$	(212,005	)	$	(177,377	)
Net cash provided by (used in) investing activities		174,304			(252,719	)
Net cash provided by financing activities		2,602			303,536
Effect of exchange rate changes on cash and cash equivalents		67			(674	)
Net decrease in cash and cash equivalents	$	(35,032	)	$	(127,234	)

Operating Activities

Net cash used in operating activities for all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. Net cash used in operating activities increased $34.6 million during the nine months ended September 30, 2016 compared to same period in the prior year, primarily driven by an increase in payments for accrued research and development costs.

Investing Activities

Net cash provided by investing activities for the nine months ended September 30, 2016 includes $175.0 million in maturities of available-for-sale securities compared to net purchases of $251.5 million for the same period in the prior year.

Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2016 and 2015 includes $2.6 million and $5.0 million, respectively, received from employee stock option exercises and stock purchases under the employee stock purchase plan. In addition, we completed the sale of $298.5 million of common stock during the nine months ended September 30, 2015.

Operating Capital Requirements

Assuming we successfully complete clinical trials and obtain requisite regulatory approvals, we do not anticipate commercializing any of our product candidates until at least the fourth quarter of 2016. As such, we anticipate that we will continue to generate significant losses for the foreseeable future as we incur expenses to complete our development activities for our programs, prepare for the potential commercial launch of our products and expand our general and administrative functions to support the growth in our research and development and commercial organizations.

As of September 30, 2016, we had cash, cash equivalents and available-for-sale securities totaling $318.8 million and total current liabilities of $59.1 million. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities as of September 30, 2016 will allow us to fund our operating plan through at least the next 12 months. We expect to finance future cash flow needs through the public or private sale of equity or debt securities, collaborations, strategic alliances or other similar licensing arrangements. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. The sale of additional equity and debt securities may result in additional dilution to our shareholders.

In addition, if we raise additional funds through the issuance of debt securities or preferred stock, these securities may have rights senior to those of our common stock and could contain covenants that would restrict our operations. Furthermore, any such required additional capital may not be available on reasonable terms, if at all. If we were unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned development and commercialization activities, which could harm our business.

Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including but not limited to:

•

the number and characteristics of the product candidates, companion diagnostics and indications we pursue;

•

the achievement of various development, regulatory and commercial milestones resulting in required payments to partners pursuant to the terms of our license agreements;

•

the scope, progress, results and costs of researching and developing our product candidates and related companion diagnostics and conducting clinical and non-clinical trials;

•

the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates and companion diagnostics;

•

the cost of commercialization activities, if any, assuming our product candidates are approved for sale, including marketing and distribution costs;

•

the cost of manufacturing any of our product candidates we successfully commercialize;

•

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and

•

the timing, receipt and amount of sales, if any, of our product candidates.

Contractual Obligations and Commitments

For a discussion of our contractual obligations, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2015 Annual Report on Form 10-K. There have not been any material changes to such contractual obligations or potential milestone payments since December 31, 2015, except as discussed in Note 12 and Note 15. For further information regarding our contractual obligations and commitments, see Note 14 to our unaudited consolidated financial statements included elsewhere in this report.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk related to changes in interest rates. As of September 30, 2016, we had cash, cash equivalents and available-for-sale securities of $318.8 million, consisting of bank demand deposits, money market funds and U.S. treasury securities. The primary objectives of our investment policy are to preserve principal and maintain proper liquidity to meet operating needs. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Our available-for-sale securities are subject to interest rate risk and will decline in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our portfolio.

We contract with contract research organizations, investigational sites and contract manufacturers globally where payments are made in currencies other than the U.S. dollar. In addition, a significant portion of the contingent purchase consideration liability will be settled with Euro-denominated payments if certain future milestones are achieved. We may be subject to fluctuations in foreign currency rates in connection with these agreements and future contingent payments. While we periodically hold foreign currencies, primarily Euro and pounds sterling, we do not use other financial instruments to hedge our foreign exchange risk. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. As of September 30, 2016 and December 31, 2015, approximately 1% and 3%, respectively, of our total liabilities were denominated in currencies other than the functional currency.

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (“Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. With the participation of our Chief Executive Officer and Principal Financial and Accounting Officer, management performed an evaluation as of September 30, 2016 of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and Principal Financial and Accounting Officer concluded that, as of September 30, 2016, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

The Consolidated Complaint names as defendants the Company and certain of its current and former officers (the “Clovis Defendants”), certain underwriters (the “Underwriter Defendants”) for a Company follow-on offering conducted in July 2015 (the “July 2015 Offering”) and certain Company venture capital investors (the “Venture Capital Defendants”). The Consolidated Complaint alleges that defendants violated particular sections of the Securities Exchange Act of 1934 (the “Exchange Act”) and the Securities Act of 1933 (the “Securities Act”). The purported misrepresentations and omissions concern allegedly misleading statements about rociletinib. The consolidated action is purportedly brought on behalf of investors who purchased the Company’s securities between May 31, 2014 and April 7, 2016 (with respect to the Exchange Act claims) and investors who purchased the Company’s securities pursuant or traceable to the July 2015 Offering (with respect to the Securities Act claims). The Consolidated Complaint seeks unspecified compensatory and recessionary damages.

On May 23, 2016, the Medina, Kimbro, Rocco, and Moran actions were consolidated for all purposes in a single proceeding in the District of Colorado.

The Clovis Defendants, the Underwriter Defendants and the Venture Capital Defendants filed a Motion to Dismiss on July 27, 2016, the Arkin Plaintiffs opposition is due on September 23, 2016, and the defendants filed their replies on October 14, 2016.

The Company intends to vigorously defend against the allegations contained in the Electrical Workers Amended Complaint, but there can be no assurance that the defense will be successful.

We received a letter dated May 31, 2016 from an alleged owner of our common stock, which purports to set forth a demand for inspection of certain of our books and records pursuant to 8 Del. C. § 220 (the “Demand Letter”). The Demand Letter was purportedly made for the purposes of investigating alleged misconduct at the Company relating to rociletinib. On June 24, 2016, we submitted a response to the Demand Letter. We believe that the Demand Letter fails to establish an entitlement to any of the requested documents, but there can be no assurance about the likelihood of an adverse outcome.

ITEM 1A.

RISK FACTORS

Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the risk factors described under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, in addition to other information contained in or incorporated by reference into this Quarterly Report on Form 10-Q and our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

There have been no material changes to the risk factors included in our previously filed Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial also may negatively impact our business.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

INDEX TO EXHIBITS

Exhibit Number		Exhibit Description

3.1(5)		Amended and Restated Certificate of Incorporation of Clovis Oncology, Inc.

3.2(5)		Amended and Restated Bylaws of Clovis Oncology, Inc.

4.1(3)		Form of Common Stock Certificate of Clovis Oncology, Inc.

4.2(8)		Indenture dated as of September 9, 2014, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A.

10.1*(4)		Amended and Restated Strategic License Agreement, dated as of June 16, 2011, by and between Clovis Oncology, Inc. and Avila Therapeutics, Inc.

10.2*(4)		License Agreement, dated as of June 2, 2011, by and between Clovis Oncology, Inc. and Pfizer Inc.

10.3+(1)		Clovis Oncology, Inc. 2009 Equity Incentive Plan.

10.4+(4)		Clovis Oncology, Inc. 2011 Stock Incentive Plan.

10.5+(1)		Form of Clovis Oncology, Inc. 2009 Equity Incentive Plan Stock Option Agreement.

10.6+(4)		Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan Stock Option Agreement.

10.7+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.8+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Erle T. Mast.

10.9+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.10+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Andrew R. Allen.

10.11+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Paul Klingenstein.

10.12+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and James C. Blair.

10.13+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Edward J. McKinley.

10.14+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Thorlef Spickschen.

10.15+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and M. James Barrett.

10.16+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Brian G. Atwood.

10.17+(1)		Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.18+(1)		Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Erle T. Mast.

10.19+(1)		Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.20+(1)		Indemnification Agreement, dated as of May 13, 2009, between Clovis Oncology, Inc. and Andrew R. Allen.

10.21+(4)		Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan.

10.22+(4)		Clovis Oncology, Inc. 2011 Cash Bonus Plan.

10.23+(6)		Employment Agreement, dated as of March 22, 2012, by and between Clovis Oncology, Inc. and Steven L. Hoerter.

10.24+(6)		Indemnification Agreement, dated as of March 22, 2012, by and between Clovis Oncology, Inc. and Steven L. Hoerter.

10.25+(2)		Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Ginger L. Graham.

10.26+(2)		Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Keith Flaherty.

10.27(7)		Stock Purchase Agreement, dated as of November 19, 2013, by and among the Company, EOS, the Sellers listed on Exhibit A thereto and Sofinnova Capital V FCPR, acting in its capacity as the Sellers’ Representative.

10.28*(7)		Development and Commercialization Agreement, dated as of October 24, 2008, by and between Advenchen Laboratories LLC and Ethical Oncology Science S.p.A., as amended by the First Amendment, dated as of April 13, 2010 and the Second Amendment, dated as of July 30, 2012.

10.29*(7)		Collaboration and License Agreement, dated as of September 28, 2012, by and between Ethical Oncology Science S.p.A. and Les Laboratoires Servier and Institut de Recherches Internationales Servier.

10.30(9)		Consulting Agreement, dated August 6, 2015, by and between Andrew Allen and Clovis Oncology, Inc.

10.31+(10)		Indemnification Agreement, dated as of January 29, 2016, by and between Clovis Oncology, Inc. and Lindsey Rolfe.

10.32+(10)		Employment Agreement, dated as of February 25, 2016, by and between Clovis Oncology, Inc. and Lindsey Rolfe.

10.33+(10)		Indemnification Agreement, dated as of January 26, 2016, by and between Clovis Oncology, Inc. and Dale Hooks.

10.34+(10)		Employment Agreement, dated as of January 26, 2016, by and between Clovis Oncology, Inc. and Dale Hooks.

10.35+(11)		Indemnification Agreement, dated as of February 17, 2016, by and between Clovis Oncology, Inc. and Daniel W. Muehl.

10.36+(12)		Offer Letter, dated as of May 27, 2015, by and between Clovis Oncology, Inc. and Daniel W. Muehl.

10.37+(12)		Salary Waiver Letter, dated as of May 9, 2016, by and between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.38*		First Amendment to License Agreement, by and between Clovis Oncology, Inc. and Pfizer Inc., dated as of August 30, 2016.

31.1		Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2		Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1		Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from Clovis Oncology, Inc.’s Quarterly Report on Form 10-Q for the period ended June 30, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Statements of Operations, (ii) the Consolidated Statements of Comprehensive Loss, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows and (v) Notes to Unaudited Consolidated Financial Statements.

(1)	Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on June 23, 2011.

(2)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on June 14, 2013.

(3)	Filed as an exhibit with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on August 31, 2011.

(4)	Filed as an exhibit with Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on October 31, 2011.

(5)	Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on March 15, 2012.

(6)	Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-180293) on March 23, 2012.

(7)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on November 19, 2013.

(8)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on September 9, 2014.

(9)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on August 12, 2015.

(10)	Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 29, 2016.

(11)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on April 1, 2016.

(12)	Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on May 9, 2016.

+	Indicates management contract or compensatory plan.

*	Confidential treatment has been granted with respect to portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 4, 2016	CLOVIS ONCOLOGY, INC.

	By:	/s/ PATRICK J. MAHAFFY
		Patrick J. Mahaffy
		President and Chief Executive Officer; Director

	By:	/s/ DANIEL W. MUEHL
		Daniel W. Muehl
		Senior Vice President of Finance and Principal Financial and Accounting Officer

EX-10.38 2 clvs-ex1038_282.htm EX-10.38 clvs-ex1038_282.htm

Exhibit 10.38

Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.

First Amendment to License Agreement

between

Clovis Oncology, Inc.

and

Pfizer, Inc.

August 30, 2016

FIRST AMENDMENT TO LICENSE AGREEMENT

This First Amendment to License Agreement (the “Amendment”) is effective as of August 30, 2016 (the “Amendment Date”) between Clovis Oncology, Inc. (“Clovis”) and Pfizer, Inc. (“Pfizer”).

Whereas, Clovis and Pfizer are parties to that certain License Agreement between Clovis and Pfizer dated June 2, 2011 (the “Agreement”).

Now, Therefore, in consideration of the foregoing premises and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Clovis and Pfizer agree as follows:

1.Capitalized terms used but not expressly defined in this Amendment have the meanings set forth in the Agreement.

2.Section 5.1.2 of the Agreement is hereby amended to add a new subsection (d) as follows:

“(d)The Milestone Payments set forth in Section 5.1.2(ii) and payable “Upon FDA approval of an NDA for 1^st Indication in US” and “Upon EMA approval of an MAA for 1^st Indication in EU” may be paid, at the election of LICENSEE, which election will be provided in writing to PFIZER within five (5) days following the applicable Milestone, either (i) pursuant to the terms of the first paragraph of Section 5.1.2, or (ii) by the date that is 18 months after the achievement of such Milestone and in the amount of *** for each such Milestone that is so deferred by LICENSEE. In the event that LICENSEE does not provide PFIZER with written notice within five (5) days following the applicable Milestone then such Milestone Payment will be made pursuant to the terms of the first paragraph of Section 5.1.2. LICENSEE at its election may or may not defer each of the (i) FDA approval of an NDA for 1^st indication in US or (ii) EMA approval of an MAA for 1^st indication in EU Milestones at the time such approval may occur, as applicable.”

3.Except as specifically amended by this Amendment, Pfizer and Clovis agree and acknowledge that the terms and conditions of the Agreement remain in full force and effect.

4.This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

In Witness Whereof, the parties have executed this Amendment as of the date first written above.

Clovis Oncology, Inc.Pfizer, Inc.

By: /s/ Daniel W. MuehlBy: /s/ Liz Barrett

Name: Daniel W. MuehlName: Liz Barrett

Title: V.P. FinanceTitle: Global President, Pfizer Oncology

EX-31.1 3 clvs-ex311_7.htm EX-31.1 clvs-ex311_7.htm

Exhibit 31.1

I, Patrick J. Mahaffy, certify that:

I have reviewed this quarterly report on Form 10-Q of Clovis Oncology, Inc. for the quarter ended September 30, 2016;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 4, 2016

/s/ PATRICK J. MAHAFFY

Patrick J. Mahaffy

President and Chief Executive Officer

EX-31.2 4 clvs-ex312_9.htm EX-31.2 clvs-ex312_9.htm

Exhibit 31.2

I, Daniel W. Muehl, certify that:

I have reviewed this quarterly report on Form 10-Q of Clovis Oncology, Inc. for the quarter ended September 30, 2016;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 4, 2016

/s/ DANIEL W. MUEHL

Daniel W. Muehl

Senior Vice President of Finance and Principal Financial and Accounting Officer

EX-32.1 5 clvs-ex321_6.htm EX-32.1 clvs-ex321_6.htm

Exhibit 32.1

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission (the “Report”), Patrick J. Mahaffy, as Chief Executive Officer of the Company, does hereby certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to his knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 4, 2016

/s/ PATRICK J. MAHAFFY

Patrick J. Mahaffy

President and Chief Executive Officer

EX-32.2 6 clvs-ex322_8.htm EX-32.2 clvs-ex322_8.htm

Exhibit 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission (the “Report”), Daniel W. Muehl, as Principal Financial and Accounting Officer of the Company, does hereby certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to his knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 4, 2016

/s/ DANIEL W. MUEHL

Daniel W. Muehl

Senior Vice President of Finance and Principal Financial and Accounting Officer

EX-101.INS 7 clvs-20160930.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares clvs:Segment iso4217:EUR pure clvs:TD 0001466301 2016-01-01 2016-09-30 0001466301 2016-10-28 0001466301 2016-07-01 2016-09-30 0001466301 2015-07-01 2015-09-30 0001466301 2015-01-01 2015-09-30 0001466301 2016-09-30 0001466301 2015-12-31 0001466301 2014-12-31 0001466301 2015-09-30 0001466301 clvs:EthicalOncologyScienceSpAMember 2013-11-18 2013-11-19 0001466301 clvs:EthicalOncologyScienceSpAMember us-gaap:CommonStockMember 2013-11-18 2013-11-19 0001466301 clvs:EthicalOncologyScienceSpAMember 2013-11-19 0001466301 clvs:EthicalOncologyScienceSpAMember clvs:RegulatoryAndSalesMilestonesMember 2013-11-19 0001466301 clvs:EthicalOncologyScienceSpAMember 2016-04-01 2016-06-30 0001466301 clvs:EthicalOncologyScienceSpAMember 2016-09-30 0001466301 clvs:EthicalOncologyScienceSpAMember 2015-12-31 0001466301 us-gaap:MoneyMarketFundsMember 2016-09-30 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001466301 us-gaap:USTreasurySecuritiesMember 2016-09-30 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001466301 us-gaap:FairValueInputsLevel1Member 2016-09-30 0001466301 us-gaap:FairValueInputsLevel2Member 2016-09-30 0001466301 us-gaap:MoneyMarketFundsMember 2015-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001466301 us-gaap:USTreasurySecuritiesMember 2015-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001466301 us-gaap:FairValueInputsLevel1Member 2015-12-31 0001466301 us-gaap:FairValueInputsLevel2Member 2015-12-31 0001466301 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001466301 us-gaap:FairValueInputsLevel3Member 2016-01-01 2016-09-30 0001466301 us-gaap:FairValueInputsLevel3Member 2016-09-30 0001466301 2016-04-01 2016-06-30 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2016-04-01 2016-06-30 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2016-09-30 0001466301 us-gaap:SeniorNotesMember 2016-09-30 0001466301 us-gaap:SeniorNotesMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001466301 us-gaap:USTreasurySecuritiesMember 2016-09-30 0001466301 us-gaap:USTreasurySecuritiesMember 2015-12-31 0001466301 us-gaap:USTreasurySecuritiesMember 2015-01-01 2015-12-31 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2015-12-31 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2014-12-31 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2016-01-01 2016-09-30 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2015-01-01 2015-12-31 0001466301 clvs:EthicalOncologyScienceSpAMember 2014-12-31 0001466301 clvs:EthicalOncologyScienceSpAMember 2016-01-01 2016-09-30 0001466301 clvs:EthicalOncologyScienceSpAMember 2015-01-01 2015-12-31 0001466301 2015-10-01 2015-12-31 0001466301 clvs:EthicalOncologyScienceSpAMember 2016-01-01 2016-03-31 0001466301 us-gaap:SeniorNotesMember 2014-09-09 0001466301 us-gaap:SeniorNotesMember 2014-09-08 2014-09-09 0001466301 us-gaap:SeniorNotesMember 2016-01-01 2016-09-30 0001466301 us-gaap:SeniorNotesMember clvs:SemiAnnualPaymentFirstPaymentMember 2016-01-01 2016-09-30 0001466301 us-gaap:SeniorNotesMember clvs:SemiAnnualPaymentSecondPaymentMember 2016-01-01 2016-09-30 0001466301 us-gaap:SeniorNotesMember 2015-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0001466301 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2015-01-01 2015-12-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-12-31 0001466301 2015-01-01 2015-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0001466301 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-09-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-09-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2016-09-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-09-30 0001466301 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-01 2016-09-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001466301 us-gaap:ExecutiveOfficerMember us-gaap:PerformanceSharesMember 2015-01-01 2015-03-31 0001466301 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2016-09-30 0001466301 us-gaap:LicenseAgreementTermsMember clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2011-06-01 2011-06-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2014-04-01 2014-04-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2016-01-01 2016-09-30 0001466301 us-gaap:LicenseAgreementTermsMember clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2016-01-01 2016-09-30 0001466301 us-gaap:LicenseAgreementTermsMember clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember clvs:FirstApprovalOfNewDrugApplicationMember 2016-01-01 2016-09-30 0001466301 us-gaap:LicenseAgreementTermsMember clvs:AdvenchenLaboratoriesLLCMember clvs:LicenseAgreementsLucitanibMember 2008-10-01 2008-10-31 0001466301 us-gaap:LicenseAgreementTermsMember clvs:AdvenchenLaboratoriesLLCMember clvs:LicenseAgreementsLucitanibMember 2014-01-01 2014-03-31 0001466301 clvs:LicenseAgreementsLucitanibMember 2014-01-01 2014-03-31 0001466301 clvs:LicenseAgreementsLucitanibMember 2012-09-01 2012-09-30 0001466301 clvs:LicenseAgreementsLucitanibMember 2012-09-30 0001466301 clvs:LicenseAgreementsLucitanibMember 2016-09-30 0001466301 clvs:LicenseAgreementsLucitanibMember 2015-12-31 0001466301 clvs:LicenseAgreementsLucitanibMember 2016-07-01 2016-09-30 0001466301 clvs:LicenseAgreementsLucitanibMember 2015-07-01 2015-09-30 0001466301 clvs:LicenseAgreementsLucitanibMember 2016-01-01 2016-09-30 0001466301 clvs:LicenseAgreementsLucitanibMember 2015-01-01 2015-09-30 0001466301 us-gaap:LicenseAgreementTermsMember clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:LicenseAgreementsRociletinibMember 2010-05-01 2010-05-31 0001466301 clvs:RegulatoryMilestonePaymentMember us-gaap:LicenseAgreementTermsMember clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:LicenseAgreementsRociletinibMember 2012-01-01 2012-03-31 0001466301 clvs:RegulatoryMilestonePaymentMember us-gaap:LicenseAgreementTermsMember clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:LicenseAgreementsRociletinibMember 2014-01-01 2014-03-31 0001466301 clvs:RegulatoryMilestonePaymentMember us-gaap:LicenseAgreementTermsMember clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:LicenseAgreementsRociletinibMember 2015-07-01 2015-09-30 0001466301 us-gaap:LicenseAgreementTermsMember clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:LicenseAgreementsRociletinibMember 2016-01-01 2016-09-30 0001466301 clvs:LicenseAgreementsLicensorCelgeneAvilomicsResearchIncMember clvs:LicenseAgreementsRociletinibMember 2016-01-01 2016-09-30 0001466301 us-gaap:ConvertibleDebtSecuritiesMember 2016-07-01 2016-09-30 0001466301 us-gaap:ConvertibleDebtSecuritiesMember 2015-07-01 2015-09-30 0001466301 us-gaap:StockCompensationPlanMember 2016-07-01 2016-09-30 0001466301 us-gaap:StockCompensationPlanMember 2015-07-01 2015-09-30 0001466301 us-gaap:ConvertibleDebtSecuritiesMember 2016-01-01 2016-09-30 0001466301 us-gaap:ConvertibleDebtSecuritiesMember 2015-01-01 2015-09-30 0001466301 us-gaap:StockCompensationPlanMember 2016-01-01 2016-09-30 0001466301 us-gaap:StockCompensationPlanMember 2015-01-01 2015-09-30 0001466301 2013-02-01 2013-02-28 0001466301 2016-06-22 2016-06-22 0001466301 us-gaap:SubsequentEventMember clvs:LonzaLtdMember 2016-10-03 2016-10-03 10-Q false 2016-09-30 2016 Q3 CLVS CLOVIS ONCOLOGY, INC. 0001466301 --12-31 Large Accelerated Filer 38585662

54338000

76138000

196675000

193256000

9162000

8331000

28541000

22286000

500000

12000000

800000

12000000

104517000

-783000

24936000

-2271000

64000000

97252000

305597000

229813000

-64000000

-97252000

-305597000

-229813000

2108000

2099000

6318000

6271000

-66000

-101000

-434000

2004000

252000

179000

473000

252000

-1922000

-2021000

-6279000

-4015000

-65922000

-99273000

-311876000

-233828000

-227000

-628000

-33467000

-508000

-65695000

-98645000

-278409000

-233320000

-1.70

-2.62

-7.24

-6.62

38538000

37613000

38429000

35252000

58000

416000

2190000

-17186000

-18000

7000

260000

148000

40000

423000

2450000

-17038000

-65655000

-98222000

-275959000

-250358000

243724000

278756000

75054000

249832000

7376000

3377000

5194000

7736000

331348000

539701000

4707000

4946000

101500000

60748000

59327000

1821000

7912000

398624000

713386000

11076000

11260000

36088000 53011000

11906000

11305000

59070000

75576000

24661000

266000

31133000

280813000

279885000

1437000

1481000

341586000

412736000

39000

38000

1162324000

1129978000

-45010000

-47460000

-1060315000

-781906000

57038000

300650000

398624000

713386000

0.001

10000000

0.001

100000000

38582755

38359454

38582755

38359454

29744000

29458000

819000

548000

-190000

-1319000

928000

900000

-24661000

-32000

-105000

-33320000

-529000

14877000 -21046000

-2358000

3500000

-322000

6124000

923000

609000

-212005000

-177377000

761000

1175000

65000

392540000

175000000

140996000

174304000

-252719000

298509000

2602000

5027000

2602000

303536000

67000

-674000

-35032000

-127234000

482677000

355443000

7188000

7307000

<div> 2. Summary of Significant Accounting Policies Our significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Form 10-K”). Recently Issued Accounting Standards In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU No. 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. The guidance also requires the presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. This update is effective for annual periods beginning after December 15, 2016, including interim periods within those annual periods. Early adoption is permitted. Amendments related to the timing of when excess tax benefits are recognized should be applied using a modified retrospective transition method. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. We are currently evaluating our planned method of adoption and the impact the standard may have on our consolidated financial statements and related disclosures.</div>

<div> 4. Financial Instruments and Fair Value Measurements Cash, Cash Equivalents and Available-for-Sale Securities We consider all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations. Marketable securities are considered to be available-for-sale securities and consist of U.S. Treasury securities. Available-for-sale securities are reported at fair value on the Consolidated Balance Sheets and unrealized gains and losses are included in accumulated other comprehensive income (loss) on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense) on the Consolidated Statements of Operations. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on our intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs. Fair Value Measurements Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="top" style="width:9%;"> Level 1:</td> <td valign="bottom" style="width:1%;">   </td> <td valign="top" style="width:70%;"> Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.</td> </tr> <tr> <td valign="top" style="width:9%;">  </td> <td valign="bottom" style="width:1%;">  </td> <td valign="top" style="width:70%;">  </td> </tr> <tr> <td valign="top" style="width:9%;"> Level 2:</td> <td valign="bottom" style="width:1%;">   </td> <td valign="top" style="width:70%;"> Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.</td> </tr> <tr> <td valign="top" style="width:9%;">  </td> <td valign="bottom" style="width:1%;">  </td> <td valign="top" style="width:70%;">  </td> </tr> <tr> <td valign="top" style="width:9%;"> Level 3:</td> <td valign="bottom" style="width:1%;">   </td> <td valign="top" style="width:70%;"> Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets that are measured at fair value on a recurring basis. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired with the purchase of EOS is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. See Note 3 of our 2015 Form 10-K for further discussion of the unobservable inputs and valuation techniques related to the contingent purchase consideration liability.</td> </tr> </table></div> The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,182</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,182</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets at fair value</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302,236</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,182</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent purchase consideration</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities at fair value</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251,037</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251,037</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,832</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,832</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets at fair value</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500,869</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251,037</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,832</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent purchase consideration</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,661</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,661</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities at fair value</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,661</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,661</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the nine months ended September 30, 2016.   The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,661</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value (a)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,936</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in foreign currency gains and losses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> (a)</td> <td valign="top"> During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At September 30, 2016, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets was zero due to the uncertainty of achieving any of the lucitanib regulatory milestones. </td></tr></table></div>   The change in the fair value of Level 3 instruments is included in change in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations. Assets measured at fair value on a nonrecurring basis include our in-process research and development (“IPR&D”) intangible assets, which were recorded as part of the acquisition of EOS (see Note 3 and Note 7). The fair value of the IPR&D intangible assets was established based upon discounted cash flow models using assumptions related to the timing of development, probability of development and regulatory success, sales and commercialization factors and estimated product life. As the valuation is based on significant unobservable inputs, the fair value measurement is classified as Level 3. IPR&D assets are evaluated for impairment at least annually or more frequently if impairment indicators exist. During the second quarter of 2016, we recorded a $104.5 million impairment charge due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At September 30, 2016, the IPR&D intangible asset recorded on the Consolidated Balance Sheets was zero. Financial instruments not recorded at fair value include our convertible senior notes. At September 30, 2016, the carrying amount of the convertible senior notes was $287.5 million, which represents the aggregate principal amount, and the fair value was $273.8 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 9 for discussion of the convertible senior notes.</div>

<div> 5. Available-for-Sale Securities As of September 30, 2016, available-for-sale securities consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,024</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   As of December 31, 2015, available-for-sale securities consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,215</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(383</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,832</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   As of September 30, 2016, there were no available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months.   As of December 31, 2015, the fair value and gross unrealized losses of available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months were as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,832</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(383</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div> As of September 30, 2016, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in one year or less</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,024</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,024</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> 6. Other Current Assets Other current assets were comprised of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivable from partners</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,258</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,241</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses- other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,613</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,023</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivable - other</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">825</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">889</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,231</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivable from landlord</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,153</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,194</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,736</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> 11. Share-Based Compensation Share-based compensation expense for all equity based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and nine months ended September 30, 2016 and 2015 was recognized in the accompanying Consolidated Statements of Operations as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,039</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,039</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,962</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,798</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,164</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,367</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,782</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,660</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,203</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,406</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,744</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,458</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   We did not recognize a tax benefit related to share-based compensation expense during the three and nine months ended September 30, 2016 and 2015, respectively, as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of September 30, 2016. The following table summarizes the activity relating to our options to purchase common stock for the nine months ended September 30, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value (Thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2015</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,360,257</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.53</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,829,537</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.85</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139,396</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.85</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,309,127</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54.27</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2016 (a)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741,271</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.51</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,392</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,351,476</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.80</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,604</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at September 30, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,954,077</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.14</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,713</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> (a)</td> <td valign="top"> Includes 42,500 performance-based stock options granted to our executives in the first quarter of 2015, which vest contingent on approval by the U.S. Food and Drug Administration (“FDA”) to commercially distribute, sell or market rucaparib. Stock compensation expense will be recognized when the condition for vesting is probable of being met. </td></tr></table></div>   The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $36.05 as of September 30, 2016, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date. The following table summarizes information about our stock options as of and for the three and nine months ended September 30, 2016 and 2015:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.26%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value per share</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.09</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56.22</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.07</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.98</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic value of options exercised</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">930,417</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,307,365</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,555,342</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,361,206</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash received from stock option exercises</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">687,332</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,953,938</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,094,855</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,534,288</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   As of September 30, 2016, the unrecognized share-based compensation expense related to unvested options, adjusted for expected forfeitures, was $83.7 million and the estimated weighted-average remaining vesting period was 2.8 years.   During 2016, we issued restricted stock units (“RSUs”) to certain employees under the 2011 Stock Incentive Plan. The RSUs vest over either a two-year period or over a four-year period and are payable in shares of our common stock at the end of the vesting period. RSUs are measured based on the fair value of the underlying stock on the grant date. Shares issued on the vesting dates are net of the minimum statutory tax to be paid by us on behalf of our employees. As a result, the actual number of shares issued will be lower than the actual number of RSUs vested.   The following table summarizes the activity relating to our unvested RSUs for the nine months ended September 30, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Units</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested as of December 31, 2015</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">526,180</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.65</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested (a)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,750</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.37</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,245</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.24</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested as of September 30, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483,185</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.86</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to vest after September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398,525</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.80</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> (a)</td> <td valign="top"> During the second quarter of 2016, we accelerated the vesting of RSUs for certain employees.</td></tr></table></div>   As of September 30, 2016, the unrecognized share-based compensation expense related to unvested RSUs, adjusted for expected forfeitures, was $8.4 million and the estimated weighted-average remaining vesting period was 3.4 years.</div>

<div> Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation. These reclassifications had no effect on our previously reported results of operations, financial position or cash flows.</div>

<div> Cash, Cash Equivalents and Available-for-Sale Securities We consider all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations. Marketable securities are considered to be available-for-sale securities and consist of U.S. Treasury securities. Available-for-sale securities are reported at fair value on the Consolidated Balance Sheets and unrealized gains and losses are included in accumulated other comprehensive income (loss) on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense) on the Consolidated Statements of Operations. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on our intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.</div>

<div> Fair Value Measurements Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="top" style="width:9%;"> Level 1:</td> <td valign="bottom" style="width:1%;">   </td> <td valign="top" style="width:70%;"> Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.</td> </tr> <tr> <td valign="top" style="width:9%;">  </td> <td valign="bottom" style="width:1%;">  </td> <td valign="top" style="width:70%;">  </td> </tr> <tr> <td valign="top" style="width:9%;"> Level 2:</td> <td valign="bottom" style="width:1%;">   </td> <td valign="top" style="width:70%;"> Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.</td> </tr> <tr> <td valign="top" style="width:9%;">  </td> <td valign="bottom" style="width:1%;">  </td> <td valign="top" style="width:70%;">  </td> </tr> <tr> <td valign="top" style="width:9%;"> Level 3:</td> <td valign="bottom" style="width:1%;">   </td> <td valign="top" style="width:70%;"> Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets that are measured at fair value on a recurring basis. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired with the purchase of EOS is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. See Note 3 of our 2015 Form 10-K for further discussion of the unobservable inputs and valuation techniques related to the contingent purchase consideration liability.</td> </tr> </table></div>  </div>

<div> IPR&D intangible assets are evaluated for impairment at least annually in the fourth quarter or more frequently if impairment indicators exist and any reduction in fair value is recorded as impairment of intangible asset on the Consolidated Statements of Operations</div>

<div> The debt issuance costs are presented as a deduction from convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the Notes.</div>

<div> Accumulated Other Comprehensive Income (Loss) Accumulated other comprehensive income (loss) consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities.</div>

<div> During 2016, we issued restricted stock units (“RSUs”) to certain employees under the 2011 Stock Incentive Plan. The RSUs vest over either a two-year period or over a four-year period and are payable in shares of our common stock at the end of the vesting period. RSUs are measured based on the fair value of the underlying stock on the grant date. Shares issued on the vesting dates are net of the minimum statutory tax to be paid by us on behalf of our employees. As a result, the actual number of shares issued will be lower than the actual number of RSUs vested.</div>

<div> Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations.</div>

<div> Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.</div>

<div> The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,182</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,182</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets at fair value</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302,236</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,182</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent purchase consideration</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities at fair value</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251,037</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251,037</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,832</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,832</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets at fair value</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500,869</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251,037</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,832</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent purchase consideration</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,661</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,661</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities at fair value</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,661</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,661</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,661</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value (a)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,936</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in foreign currency gains and losses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> (a)</td> <td valign="top"> During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At September 30, 2016, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets was zero due to the uncertainty of achieving any of the lucitanib regulatory milestones. </td></tr></table></div></div>

<div> As of September 30, 2016, available-for-sale securities consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,024</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   As of December 31, 2015, available-for-sale securities consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,215</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(383</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,832</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> As of December 31, 2015, the fair value and gross unrealized losses of available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months were as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,832</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(383</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>  </div>

<div> As of September 30, 2016, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in one year or less</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,024</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,024</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,054</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IPR&D intangible assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,900</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of intangible asset (a)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104,517</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,557</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in foreign currency gains (losses)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,843</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Goodwill:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,327</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,055</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in foreign currency gains (losses)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,728</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,748</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,327</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> (a)</td> <td valign="top"> During the second quarter of 2016, we recorded a $104.5 million impairment charge due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At September 30, 2016, the IPR&D intangible asset recorded on the Consolidated Balance Sheets was zero. </td></tr></table></div>   During the fourth quarter of 2015, we recorded an $89.6 million impairment charge due to our and our development partner’s decision to discontinue the development of lucitanib for lung cancer, as well as updates to the probability-weighted discounted cash flow assumptions for the breast cancer indication.</div>

<div> The following table sets forth total interest expense recognized related to the Notes during the three and nine months ended September 30, 2016 and 2015 (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:89.48%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual interest expense</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,390</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,371</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt issuance costs</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">900</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,108</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,318</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,271</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Losses)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance December 31, 2014</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,448</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,448</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Period change</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,629</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(383</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,012</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance December 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,077</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(383</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,460</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Period change</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,526</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,938</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,335</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(153</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,488</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance September 30, 2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,886</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(124</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,010</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>  </div>

<div> Share-based compensation expense for all equity based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and nine months ended September 30, 2016 and 2015 was recognized in the accompanying Consolidated Statements of Operations as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,039</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,039</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,962</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,798</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,164</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,367</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,782</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,660</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,203</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,406</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,744</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,458</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table summarizes the activity relating to our options to purchase common stock for the nine months ended September 30, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value (Thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2015</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,360,257</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.53</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,829,537</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.85</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139,396</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.85</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,309,127</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54.27</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2016 (a)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,741,271</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.51</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,392</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,351,476</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.80</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,604</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at September 30, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,954,077</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.14</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,713</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> (a)</td> <td valign="top"> Includes 42,500 performance-based stock options granted to our executives in the first quarter of 2015, which vest contingent on approval by the U.S. Food and Drug Administration (“FDA”) to commercially distribute, sell or market rucaparib. Stock compensation expense will be recognized when the condition for vesting is probable of being met. </td></tr></table></div></div>

<div> The following table summarizes information about our stock options as of and for the three and nine months ended September 30, 2016 and 2015:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.26%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value per share</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.09</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56.22</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.07</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52.98</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic value of options exercised</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">930,417</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,307,365</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,555,342</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,361,206</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash received from stock option exercises</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">687,332</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,953,938</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,094,855</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,534,288</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table summarizes the activity relating to our unvested RSUs for the nine months ended September 30, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Units</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested as of December 31, 2015</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">526,180</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.65</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested (a)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,750</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.37</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,245</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.24</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested as of September 30, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483,185</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.86</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to vest after September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398,525</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.80</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> (a)</td> <td valign="top"> During the second quarter of 2016, we accelerated the vesting of RSUs for certain employees.</td></tr></table></div></div>

<div> The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three and Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible senior notes</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,646</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,646</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common shares under options and awards</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,772</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,232</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total potential dilutive shares</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,418</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,878</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

11800000

173700000

193500000

65000000

115000000

-25500000

24700000

227182000

75054000

302236000

227182000

75054000

251037000

249832000

500869000

251037000

249832000

24661000

-24936000

275000

-25500000

104500000

287500000

273800000

75024000

30000

75054000

250215000

383000

249832000

383000

75024000

75054000

1258000

3241000

2613000

1023000

825000

889000

406000

1231000

1153000

92000

199000

101500000

212900000

104517000

89557000

3017000

-21843000

59327000

66055000

1421000

-6728000

60748000

104500000

89600000

-3600000

-29200000

10345000

8250000

299000

2096000

1262000

959000

287500000

0.025

278300000

semi-annually

2021-09-15

--03-15 --09-15

61.88

16.1616

1.50

P30D

1.00

2018-09-15

P2D 1.00

9200000

P7Y

6700000

7600000

1797000

5390000

5371000

311000

302000

-24448000

-22629000

-383000

-23012000

-47077000

-383000

-47460000

3526000

412000

3938000

1335000

153000

1488000

-44886000

-124000

-45010000

7039000

9039000

20962000

19798000

2164000

3367000

8782000

9660000

9203000

12406000

29744000

29458000

5360257

1829537

139396

1309127

5741271

5351476

2954077

51.53

21.85

7.85

54.27

42.51

42.80

43.14

P7Y4M24D

P7Y2M12D

P5Y9M18D

52392000

48604000

27713000

42500

36.05

17.09

56.22

16.07

52.98

930417

5307365

1555342

15361206

687332

1953938

1094855

4534288

83700000

P2Y9M18D

526180

9750

33245

483185

398525

21.65

19.37

19.24

21.86

21.80

8400000

P3Y4M24D

7000000

400000

500000

264500000 21250000 0.25

3400000

13600000 45000000 90000000 250000000 80000000

1300000

3200000

1300000

3800000

7400000

11700000

1300000 3800000 7700000 10400000 2000000

4000000

5000000

12000000

98000000 120000000

4646000

3772000

5232000

8418000

9878000

4646000

3772000

5232000

8418000

9878000

48500000

P24M P12M P30D 2025-12-31 P90D

EX-101.SCH 8 clvs-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Nature of Business and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - EOS Acquisition link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Financial Instruments and Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Available-for-Sale Securities link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Other Current Assets link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Intangible Assets and Goodwill link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Other Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Convertible Senior Notes link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Share-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - License Agreements link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Net Loss Per Common Share link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Nature of Business and Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Available-for-Sale Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Other Current Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Intangible Assets and Goodwill (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Other Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Convertible Senior Notes (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Share-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Net Loss Per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - EOS Acquisition - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Available-for-Sale Securities - Summary of Available-for-Sale Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Available-for-Sale Securities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Other Current Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Summary of IPR&D Intangible Assets and Goodwill (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Summary of IPR&D Intangible Assets and Goodwill (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Intangible Assets and Goodwill - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Other Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Convertible Senior Notes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Schedule of Total Interest Expense Recognized Related to Notes (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Component of Other Comprehensive Income (Loss) (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Summary of Stock Options Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Summary of Stock Options Activity (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Summary of Activity Relating to Company's Unvested Restricted Stock Units (Detail) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - License Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 clvs-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 clvs-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 clvs-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Income Statement [Abstract] Revenues: Revenues [Abstract] License and milestone revenue Revenue Recognition Milestone Method Revenue Recognized Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense Excluding Acquired In Process Cost General and administrative General And Administrative Expense Acquired in-process research and development Research And Development Asset Acquired Other Than Through Business Combination Written Off Impairment of intangible asset Impairment Of Intangible Assets Indefinitelived Excluding Goodwill Change in fair value of contingent purchase consideration Liabilities Fair Value Adjustment Total expenses Operating Expenses Operating loss Operating Income Loss Other income (expense): Nonoperating Income Expense [Abstract] Interest expense Interest Expense Debt Foreign currency gains (losses) Foreign Currency Transaction Gain Loss Before Tax Other income Other Nonoperating Income Expense Other expense, net Nonoperating Income Expense Loss before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax benefit Income Tax Expense Benefit Net loss Net Income Loss Basic and diluted net loss per common share Earnings Per Share Basic And Diluted Basic and diluted weighted-average common shares outstanding Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Income And Comprehensive Income [Abstract] Net loss Other comprehensive income (loss) Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Foreign currency translation adjustments, net of tax Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Net unrealized gain (loss) on available-for-sale securities, net of tax Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Other comprehensive income (loss) Other Comprehensive Income Loss Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Carrying value as of the balance sheet date of obligations incurred and payable for research and development activities which are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include contract research organizations, contract manufacturers and other research and development vendors. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Available-for-sale securities Available For Sale Securities Current Prepaid research and development expenses Prepaid Expense Current Other current assets Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Intangible assets Indefinite Lived Intangible Assets Excluding Goodwill Goodwill Goodwill Other assets Other Assets Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued research and development expenses Accrued Research And Development Expenses Other accrued expenses Accrued Liabilities Current Total current liabilities Liabilities Current Contingent purchase consideration Business Combination Contingent Consideration Liability Noncurrent Deferred income taxes, net Deferred Tax Liabilities Noncurrent Convertible senior notes Debt Instrument Carrying Amount Deferred rent, long-term Deferred Rent Credit Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 14) Commitments And Contingencies Stockholders' equity: Stockholders Equity [Abstract] Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2016 and December 31, 2015 Preferred Stock Value Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2016 and December 31, 2015; 38,582,755 and 38,359,454 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders' equity Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding The net increase (decrease) during the reporting period in the amount of outstanding money paid in advance for research and development goods and services that bring economic benefits for future periods or in the amount of other research and development expenses incurred but not yet paid. Increase (decrease) relates to amounts paid in advance, or incurred and not yet paid, to contract research organizations, contract manufacturers or other research and development vendors. Statement Of Cash Flows [Abstract] Operating activities Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Share-based compensation expense Share Based Compensation Depreciation and amortization Depreciation Depletion And Amortization Amortization of premiums and discounts on available-for-sale securities Accretion Amortization Of Discounts And Premiums Investments Amortization of debt issuance costs Amortization Of Financing Costs Change in fair value of contingent purchase consideration Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 Loss on disposal of property and equipment Gain Loss On Disposition Of Assets Deferred income taxes Deferred Income Tax Expense Benefit Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid and accrued research and development expenses Increase Decrease In Prepaid And Accrued Research And Development Expenses Other operating assets Increase Decrease In Other Operating Assets Accounts payable Increase Decrease In Accounts Payable Other accrued expenses Increase Decrease In Other Accrued Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Investing activities Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Proceeds from sale of property and equipment Proceeds From Sale Of Property Plant And Equipment Purchases of available-for-sale securities Payments To Acquire Available For Sale Securities Debt Maturities of available-for-sale securities Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities Sales of available-for-sale securities Proceeds From Sale Of Available For Sale Securities Debt Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Financing activities Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Proceeds from the sale of common stock, net of issuance costs Proceeds From Issuance Of Common Stock Proceeds from the exercise of stock options and employee stock purchases Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Effect of exchange rate changes on cash and cash equivalents Effect Of Exchange Rate On Cash And Cash Equivalents Decrease in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Organization Consolidation And Presentation Of Financial Statements [Abstract] Nature of Business and Basis of Presentation Business Description And Basis Of Presentation [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Business Combinations [Abstract] EOS Acquisition Business Combination Disclosure [Text Block] Fair Value Disclosures [Abstract] Financial Instruments and Fair Value Measurements Fair Value Disclosures [Text Block] Available For Sale Securities [Abstract] Available-for-Sale Securities Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Other current assets. Other Current Assets [Abstract] Other Current Assets Other Current Assets [Text Block] Goodwill And Intangible Assets Disclosure [Abstract] Intangible Assets and Goodwill Goodwill And Intangible Assets Disclosure [Text Block] Payables And Accruals [Abstract] Other Accrued Expenses Accounts Payable And Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Convertible Senior Notes Long Term Debt [Text Block] Equity [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Share-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] License Agreements. Research And Development [Abstract] License Agreements License Agreements [Text Block] Earnings Per Share [Abstract] Net Loss Per Common Share Earnings Per Share [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Reclassifications Prior Period Reclassification Adjustment Description Use of Estimates Use Of Estimates Liquidity. Liquidity Liquidity Policy [Text Block] Recently Issued Accounting Standards New Accounting Pronouncements Policy Policy [Text Block] Disclosure of the accounting policy for cash, cash equivalents and available-for-sale securities. Includes the policy for determining which items are treated as cash equivalents. Cash, Cash Equivalents and Available-for-Sale Securities Cash Cash Equivalents And Available For Sale Securities Policy [Text Block] Fair Value Measurements Fair Value Measurement Policy Policy [Text Block] Intangible Assets and Goodwill Goodwill And Intangible Assets Policy [Text Block] Convertible Senior Notes Debt Policy [Text Block] Accumulated Other Comprehensive Income (Loss) Stockholders Equity Policy [Text Block] Share-Based Compensation Share Based Compensation Option And Incentive Plans Policy Reimbursement. Lucitanib Reimbursement Policy [Text Block] Net Loss Per Common Share Earnings Per Share Policy [Text Block] Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Summary of Available-for-Sale Securities Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position Available For Sale Securities Continuous Unrealized Loss Position Fair Value Table [Text Block] Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity Available For Sale Securities [Text Block] Other Current Assets Schedule Of Other Current Assets Table [Text Block] Summary of IPR&D Intangible Assets and Goodwill Schedule Of Intangible Assets And Goodwill Table [Text Block] Other Accrued Expenses Schedule Of Accrued Liabilities Table [Text Block] Schedule of Total Interest Expense Recognized Related to Notes Interest Income And Interest Expense Disclosure Table [Text Block] Component of Other Comprehensive Income (Loss) Schedule Of Accumulated Other Comprehensive Income Loss Table [Text Block] Share-Based Compensation Expense Recognized in Accompanying Statements of Operations Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Stock Options Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block] Summary of Activity Relating to Company's Unvested Restricted Stock Units Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Number of operating segments Number Of Operating Segments Schedule Of Business Acquisitions By Acquisition [Table] Schedule Of Business Acquisitions By Acquisition [Table] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition Acquiree [Domain] Name of acquired company - Ethical Oncology Science SpA. Ethical Oncology Science, S.p.A. Ethical Oncology Science Sp A [Member] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Type of Arrangement and Non-arrangement Transactions Type Of Arrangement [Axis] Arrangements and Non-arrangement Transactions Arrangements And Nonarrangement Transactions [Member] Regulatory and Sales Milestones. Regulatory and Sales Milestones Regulatory And Sales Milestones [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Business acquisition cash payments made on acquisition Payments To Acquire Businesses Gross Business acquisition, common stock issued at acquisition date Stock Issued During Period Value Acquisitions Future maximum contingent milestone payments Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High Future minimum potential contingent milestone payments Business Combination Contingent Consideration Arrangements Range Of Outcomes Value Low Reduction in fair value of contingent purchase consideration liability Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Money Market Money Market Funds [Member] U.S. Treasury Securities U S Treasury Securities [Member] EX-101.PRE 12 clvs-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Oct. 28, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	CLVS
Entity Registrant Name	CLOVIS ONCOLOGY, INC.
Entity Central Index Key	0001466301
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		38,585,662

XML 14 R2.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating expenses:
Research and development	$ 54,338	$ 76,138	$ 196,675	$ 193,256
General and administrative	9,162	8,331	28,541	22,286
Acquired in-process research and development	500	12,000	800	12,000
Impairment of intangible asset			104,517
Change in fair value of contingent purchase consideration		783	(24,936)	2,271
Total expenses	64,000	97,252	305,597	229,813
Operating loss	(64,000)	(97,252)	(305,597)	(229,813)
Other income (expense):
Interest expense	(2,108)	(2,099)	(6,318)	(6,271)
Foreign currency gains (losses)	(66)	(101)	(434)	2,004
Other income	252	179	473	252
Other expense, net	(1,922)	(2,021)	(6,279)	(4,015)
Loss before income taxes	(65,922)	(99,273)	(311,876)	(233,828)
Income tax benefit	227	628	33,467	508
Net loss	$ (65,695)	$ (98,645)	$ (278,409)	$ (233,320)
Basic and diluted net loss per common share	$ (1.70)	$ (2.62)	$ (7.24)	$ (6.62)
Basic and diluted weighted-average common shares outstanding	38,538	37,613	38,429	35,252

XML 15 R3.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (65,695)	$ (98,645)	$ (278,409)	$ (233,320)
Other comprehensive income (loss)
Foreign currency translation adjustments, net of tax	58	416	2,190	(17,186)
Net unrealized gain (loss) on available-for-sale securities, net of tax	(18)	7	260	148
Other comprehensive income (loss)	40	423	2,450	(17,038)
Comprehensive loss	$ (65,655)	$ (98,222)	$ (275,959)	$ (250,358)

XML 16 R4.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 243,724	$ 278,756
Available-for-sale securities	75,054	249,832
Prepaid research and development expenses	7,376	3,377
Other current assets	5,194	7,736
Total current assets	331,348	539,701
Property and equipment, net	4,707	4,946
Intangible assets		101,500
Goodwill	60,748	59,327
Other assets	1,821	7,912
Total assets	398,624	713,386
Current liabilities:
Accounts payable	11,076	11,260
Accrued research and development expenses	36,088	53,011
Other accrued expenses	11,906	11,305
Total current liabilities	59,070	75,576
Contingent purchase consideration	0	24,661
Deferred income taxes, net	266	31,133
Convertible senior notes	280,813	279,885
Deferred rent, long-term	1,437	1,481
Total liabilities	341,586	412,736
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2016 and December 31, 2015
Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2016 and December 31, 2015; 38,582,755 and 38,359,454 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	39	38
Additional paid-in capital	1,162,324	1,129,978
Accumulated other comprehensive loss	(45,010)	(47,460)
Accumulated deficit	(1,060,315)	(781,906)
Total stockholders' equity	57,038	300,650
Total liabilities and stockholders' equity	$ 398,624	$ 713,386

XML 17 R5.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	38,582,755	38,359,454
Common stock, shares outstanding	38,582,755	38,359,454

XML 18 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities
Net loss	$ (278,409)	$ (233,320)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	29,744	29,458
Depreciation and amortization	819	548
Amortization of premiums and discounts on available-for-sale securities	190	1,319
Amortization of debt issuance costs	928	900
Impairment of intangible asset	104,517
Change in fair value of contingent purchase consideration	(24,661)	(32)
Loss on disposal of property and equipment	105
Deferred income taxes	(33,320)	(529)
Changes in operating assets and liabilities:
Prepaid and accrued research and development expenses	(14,877)	21,046
Other operating assets	2,358	(3,500)
Accounts payable	(322)	6,124
Other accrued expenses	923	609
Net cash used in operating activities	(212,005)	(177,377)
Investing activities
Purchases of property and equipment	(761)	(1,175)
Proceeds from sale of property and equipment	65
Purchases of available-for-sale securities		(392,540)
Maturities of available-for-sale securities	175,000
Sales of available-for-sale securities		140,996
Net cash provided by (used in) investing activities	174,304	(252,719)
Financing activities
Proceeds from the sale of common stock, net of issuance costs		298,509
Proceeds from the exercise of stock options and employee stock purchases	2,602	5,027
Net cash provided by financing activities	2,602	303,536
Effect of exchange rate changes on cash and cash equivalents	67	(674)
Decrease in cash and cash equivalents	(35,032)	(127,234)
Cash and cash equivalents at beginning of period	278,756	482,677
Cash and cash equivalents at end of period	243,724	355,443
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 7,188	$ 7,307

XML 19 R7.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Presentation	9 Months Ended
Nature of Business and Basis of Presentation	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	1. Nature of Business and Basis of Presentation Clovis Oncology, Inc. (the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. We have and intend to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities. Basis of Presentation All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, except for those discussed in the following footnotes, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2015 for a broader discussion of our business and the opportunities and risks inherent in such business. Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation. These reclassifications had no effect on our previously reported results of operations, financial position or cash flows. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to contingent purchase consideration, the allocation of purchase consideration, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Liquidity We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of our product candidates and achieving a level of revenues adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash. We intend to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. Based on our current estimates, we believe that our cash, cash equivalents and available-for-sale securities as of September 30, 2016 will allow us to fund activities through at least the next 12 months.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Our significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Form 10-K”). Recently Issued Accounting Standards In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU No. 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. The guidance also requires the presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. This update is effective for annual periods beginning after December 15, 2016, including interim periods within those annual periods. Early adoption is permitted. Amendments related to the timing of when excess tax benefits are recognized should be applied using a modified retrospective transition method. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. We are currently evaluating our planned method of adoption and the impact the standard may have on our consolidated financial statements and related disclosures.

XML 21 R9.htm IDEA: XBRL DOCUMENT

EOS Acquisition	9 Months Ended
EOS Acquisition	Sep. 30, 2016
Business Combinations [Abstract]
EOS Acquisition	3. EOS Acquisition On November 19, 2013, we acquired all of the outstanding common and preferred stock of Ethical Oncology Science, S.p.A. (“EOS”) (now known as Clovis Oncology Italy S.r.l.). We paid $11.8 million in cash and issued $173.7 million of common stock at the acquisition date and are obligated to pay additional future cash payments if certain lucitanib regulatory and sales milestones are achieved. The potential contingent milestone payments range from a zero payment, which assumes lucitanib fails to achieve any of the regulatory milestones, to approximately $193.5 million ($65.0 million and €115.0 million) if all regulatory and sales milestones are met, utilizing the translation rate at September 30, 2016. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer (see Note 4). At September 30, 2016, the contingent purchase consideration liability recorded on the Consolidated Balance Sheets was zero due to the uncertainty of achieving any of the lucitanib regulatory milestones. At December 31, 2015, the liability for the estimated fair value of the payments recorded on the Consolidated Balance Sheets was $24.7 million.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 22 R10.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurements

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Financial Instruments and Fair Value Measurements

4. Financial Instruments and Fair Value Measurements

Cash, Cash Equivalents and Available-for-Sale Securities

Fair Value Measurements

The three levels of inputs that may be used to measure fair value include:

Level 1:		Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.

Level 2:		Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

Level 3:		Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets that are measured at fair value on a recurring basis. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired with the purchase of EOS is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. See Note 3 of our 2015 Form 10-K for further discussion of the unobservable inputs and valuation techniques related to the contingent purchase consideration liability.

The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):

	Balance		Level 1		Level 2		Level 3
September 30, 2016
Assets:
Money market	$	227,182	$	227,182	$	—	$	—
U.S. treasury securities		75,054		—		75,054		—
Total assets at fair value	$	302,236	$	227,182	$	75,054	$	—
Liabilities:
Contingent purchase consideration	$	—	$	—	$	—	$	—
Total liabilities at fair value	$	—	$	—	$	—	$	—
December 31, 2015
Assets:
Money market	$	251,037	$	251,037	$	—	$	—
U.S. treasury securities		249,832		—		249,832		—
Total assets at fair value	$	500,869	$	251,037	$	249,832	$	—
Liabilities:
Contingent purchase consideration	$	24,661	$	—	$	—	$	24,661
Total liabilities at fair value	$	24,661	$	—	$	—	$	24,661

There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the nine months ended September 30, 2016.

The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) (in thousands):

	For the Nine
	Months Ended
	September 30, 2016
Liabilities:
Balance at beginning of period	$	24,661
Change in fair value (a)		(24,936	)
Change in foreign currency gains and losses		275
Balance at end of period	$	—

(a)

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R11.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities

9 Months Ended

Sep. 30, 2016

Available For Sale Securities [Abstract]

Available-for-Sale Securities

5. Available-for-Sale Securities

As of September 30, 2016, available-for-sale securities consisted of the following (in thousands):

			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	75,024	$	30	$	—	$	75,054

As of December 31, 2015, available-for-sale securities consisted of the following (in thousands):

			Gross		Gross			Aggregate
	Amortized		Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Value
U.S. treasury securities	$	250,215	$	—	$	(383	)	$	249,832

As of September 30, 2016, there were no available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months.

	Aggregate		Gross
	Fair		Unrealized
	Value		Losses
U.S. treasury securities	$	249,832	$	(383	)

As of September 30, 2016, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):

	Amortized		Fair
	Cost		Value
Due in one year or less	$	75,024	$	75,054
Total	$	75,024	$	75,054

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

XML 24 R12.htm IDEA: XBRL DOCUMENT

Other Current Assets

9 Months Ended

Sep. 30, 2016

Other Current Assets [Abstract]

Other Current Assets

6. Other Current Assets

Other current assets were comprised of the following (in thousands):

	September 30,		December 31,
	2016		2015
Receivable from partners	$	1,258	$	3,241
Prepaid expenses- other		2,613		1,023
Receivable - other		825		889
Prepaid insurance		406		1,231
Receivable from landlord		—		1,153
Other		92		199
Total	$	5,194	$	7,736

XML 25 R13.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill

9 Months Ended

Sep. 30, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

7. Intangible Assets and Goodwill

IPR&D intangible assets and goodwill were established as part of the purchase accounting of EOS (see Note 3) and consisted of the following (in thousands):

	September 30,			December 31,
	2016			2015
IPR&D intangible assets:
Balance at beginning of period	$	101,500		$	212,900
Impairment of intangible asset (a)		(104,517	)		(89,557	)
Change in foreign currency gains (losses)		3,017			(21,843	)
Balance at end of period	$	—		$	101,500

Goodwill:
Balance at beginning of period	$	59,327		$	66,055
Change in foreign currency gains (losses)		1,421			(6,728	)
Balance at end of period	$	60,748		$	59,327

(a)

During the second quarter of 2016, we recognized a $29.2 million deferred tax benefit associated with the impairment of the IPR&D intangible asset.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 26 R14.htm IDEA: XBRL DOCUMENT

Other Accrued Expenses

9 Months Ended

Sep. 30, 2016

Payables And Accruals [Abstract]

Other Accrued Expenses

8. Other Accrued Expenses

Other accrued expenses were comprised of the following (in thousands):

	September 30,		December 31,
	2016		2015
Accrued personnel costs	$	10,345	$	8,250
Accrued interest payable		299		2,096
Accrued expenses - other		1,262		959
Total	$	11,906	$	11,305

XML 27 R15.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Convertible Senior Notes

9. Convertible Senior Notes

The following table sets forth total interest expense recognized related to the Notes during the three and nine months ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Contractual interest expense	$	1,797	$	1,797	$	5,390	$	5,371
Amortization of debt issuance costs		311		302		928		900
Total interest expense	$	2,108	$	2,099	$	6,318	$	6,271

XML 28 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Stockholders' Equity

10. Stockholders’ Equity

Accumulated Other Comprehensive Income (Loss)

The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):

							Total
	Foreign						Accumulated
	Currency			Unrealized			Other
	Translation			Gains			Comprehensive
	Adjustments			(Losses)			Income (Loss)
Balance December 31, 2014	$	(24,448	)	$	—		$	(24,448	)
Period change		(22,629	)		(383	)		(23,012	)
Balance December 31, 2015		(47,077	)		(383	)		(47,460	)
Period change		3,526			412			3,938
Income tax expense		(1,335	)		(153	)		(1,488	)
Balance September 30, 2016	$	(44,886	)	$	(124	)	$	(45,010	)

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 29 R17.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

9 Months Ended

Sep. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-Based Compensation

11. Share-Based Compensation

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Research and development	$	7,039	$	9,039	$	20,962	$	19,798
General and administrative		2,164		3,367		8,782		9,660
Total share-based compensation expense	$	9,203	$	12,406	$	29,744	$	29,458

The following table summarizes the activity relating to our options to purchase common stock for the nine months ended September 30, 2016:

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value (Thousands)
Outstanding at December 31, 2015		5,360,257		$	51.53
Granted		1,829,537			21.85
Exercised		(139,396	)		7.85
Forfeited		(1,309,127	)		54.27
Outstanding at September 30, 2016 (a)		5,741,271		$	42.51		7.4	$	52,392
Vested and expected to vest at September 30, 2016		5,351,476		$	42.80		7.2	$	48,604
Exercisable at September 30, 2016		2,954,077		$	43.14		5.8	$	27,713

(a)

The following table summarizes information about our stock options as of and for the three and nine months ended September 30, 2016 and 2015:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Weighted-average grant date fair value per share	$	17.09	$	56.22	$	16.07	$	52.98
Intrinsic value of options exercised	$	930,417	$	5,307,365	$	1,555,342	$	15,361,206
Cash received from stock option exercises	$	687,332	$	1,953,938	$	1,094,855	$	4,534,288

The following table summarizes the activity relating to our unvested RSUs for the nine months ended September 30, 2016:

	Number of Units			Weighted- Average Grant Date Fair Value
Unvested as of December 31, 2015		—		$	—
Granted		526,180			21.65
Vested (a)		(9,750	)		19.37
Forfeited		(33,245	)		19.24
Unvested as of September 30, 2016		483,185		$	21.86
Expected to vest after September 30, 2016		398,525		$	21.80

(a)

During the second quarter of 2016, we accelerated the vesting of RSUs for certain employees.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 30 R18.htm IDEA: XBRL DOCUMENT

License Agreements	9 Months Ended
License Agreements	Sep. 30, 2016
Research And Development [Abstract]
License Agreements	12. License Agreements Rucaparib In June 2011, we entered into a worldwide license agreement with Pfizer, Inc. to acquire exclusive development and commercialization rights to rucaparib. This drug candidate is a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP), which we are developing for the treatment of selected solid tumors. Under the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer. In April 2014, we initiated a pivotal registration study for rucaparib, which resulted in a $0.4 million milestone payment to Pfizer as required by the license agreement. In September 2016, we made a milestone payment of $0.5 million to Pfizer upon acceptance of the NDA for rucaparib by the FDA. These payments were recognized as acquired in-process research and development expense. We are responsible for all development and commercialization costs of rucaparib. When and if commercial sales of rucaparib begin, we will pay Pfizer tiered royalties on our net sales. In addition, Pfizer is eligible to receive up to $264.5 million of further payments, in aggregate, if certain development, regulatory and sales milestones are achieved, including $21.25 million associated with the first filing and approval of a New Drug Application (“NDA”) by the FDA. During the second quarter of 2016, we completed the submission of our NDA with the FDA for potential accelerated approval of rucaparib in the U.S. The FDA granted the rucaparib NDA priority review status with a Prescription Drug User Fee Act action date of February 23, 2017. During the fourth quarter of 2016, we submitted a Marketing Authorization Application (“MAA”) for rucaparib to the European Medicines Agency (“EMA”). On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1^st Indication in US and (ii) EMA approval of an MAA for 1^st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones. Lucitanib In connection with its acquisition of EOS (see Note 3), we gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Les Laboratoires Servier (“Servier”) in exchange for upfront milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments. In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen royalties on net sales of lucitanib based on the volume of annual net sales achieved. In addition, we are obligated to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. In the first quarter of 2014, we recognized acquired in-process research and development expense of $3.4 million, which represents 25% of the sublicense agreement consideration of $13.6 million received from Servier upon the end of opposition and appeal of the lucitanib patent by the European Patent Office. In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an upfront payment of €45.0 million and is entitled to receive additional payments upon achievement of specified development, regulatory and commercial milestones up to €90.0 million in the aggregate. In addition, we are entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, which, in the aggregate, could total €250.0 million. We are also entitled to receive royalties on sales of lucitanib by Servier. The development, regulatory and commercial milestones represent non-refundable amounts that would be paid by Servier to us if certain milestones are achieved in the future. These milestones, if achieved, are substantive as they relate solely to past performance, are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of our performance, which are reasonable relative to the other deliverables and terms of the arrangement, and are unrelated to the delivery of any further elements under the arrangement. We and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for all of the initial global development costs under the agreed upon plan up to €80.0 million. Cumulative global development costs, if any, in excess of €80.0 million will be shared equally between us and Servier. During the second quarter of 2016, we and Servier agreed to discontinue the development of lucitanib for breast cancer and are continuing to evaluate, what, if any, further development of lucitanib will be pursued. Based on current estimates, we expect to complete the committed on-going development activities in 2017 and expect full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations. We recorded a $1.3 million and $3.2 million receivable at September 30, 2016 and December 31, 2015, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. For the three months ending September 30, 2016 and 2015, we incurred $1.3 million and $3.8 million, respectively, in research and development costs and recorded reductions in research and development expense of $1.3 million and $3.8 million, respectively, for reimbursable development costs due from Servier. For the nine months ending September 30, 2016 and 2015, respectively, we incurred $7.4 million and $11.7 million, respectively, in research and development costs and recorded reductions in research and development expense of $7.7 million and $10.4 million, respectively, for reimbursable development costs due from Servier. Rociletinib In May 2010, we entered into an exclusive worldwide license agreement with Avila Therapeutics, Inc. (now Celgene Avilomics Research, Inc., part of Celgene Corporation (“Celgene”)) to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor gene product. Rociletinib was identified as the lead inhibitor candidate under the license agreement. We are responsible for all non-clinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib. We made an upfront payment of $2.0 million upon execution of the license agreement, a $4.0 million milestone payment in the first quarter of 2012 upon acceptance by the FDA of our Investigational New Drug application for rociletinib and a $5.0 million milestone payment in the first quarter of 2014 upon initiation of the Phase II study for rociletinib. In the third quarter of 2015, we made milestone payments totaling $12.0 million upon acceptance of the NDA and MAA for rociletinib by the FDA and EMA, respectively. We recognized all payments as acquired in-process research and development expense. During the second quarter of 2016, we received a Complete Response Letter (“CRL”) from the FDA for the rociletinib NDA. The FDA issues a CRL to indicate that their review of an application is complete and that the application is not ready for approval. In anticipation of receiving the CRL, we terminated enrollment in all ongoing sponsored clinical studies, although we continue to provide drug to patients whose clinicians recommend continuing rociletinib therapy. In addition, we withdrew our MAA for rociletinib on file with the EMA. We are continuing analyses of rociletinib data to determine whether certain populations of patients may represent an opportunity for a partner committed to investing in further clinical development. We are obligated to pay royalties on net sales of rociletinib based on the volume of annual net sales achieved. We are required to pay up to an additional aggregate of $98.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are required to pay up to an aggregate of $120.0 million in sales milestone payments if certain annual sales targets are achieved.

XML 31 R19.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Net Loss Per Common Share

13. Net Loss Per Common Share

	Three and Nine Months Ended September 30,
	2016		2015
Convertible senior notes		4,646		4,646
Common shares under options and awards		3,772		5,232
Total potential dilutive shares		8,418		9,878

XML 32 R20.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Royalty and License Fee Commitments We have entered into certain license agreements, as identified in Note 12, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. Our payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, no amounts have been recorded on our Consolidated Balance Sheets at September 30, 2016 and December 31, 2015. Development and Manufacturing Agreement Commitments In February 2013, we entered into a development and manufacturing agreement with a third-party supplier for the production of the active ingredient for rucaparib. Under the Development and Manufacturing Agreement, we will provide the third-party supplier a rolling 24-month forecast that will be updated by us on a quarterly basis. We are obligated to order the quantity specified in the first 12 months of any forecast. Currently, $48.5 million of purchase commitments exist under this agreement. Legal Proceedings The Company and certain of its officers and directors were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition. On November 19, 2015, Steve Kimbro, a purported shareholder of Clovis, filed a purported class action complaint (the “Kimbro Complaint”) against Clovis and certain of its officers in the United States District Court for the District of Colorado. The Kimbro Complaint purports to be asserted on behalf of a class of persons who purchased Clovis stock between October 31, 2013 and November 15, 2015. The Kimbro Complaint generally alleges that Clovis and certain of its officers violated federal securities laws by making allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib. The Kimbro Complaint seeks unspecified damages. Also on November 19, 2015, a second purported shareholder class action complaint was filed by Sonny P. Medina, another purported Clovis shareholder, containing similar allegations to those set forth in the Kimbro Complaint, also in the United States District Court for the District of Colorado (the “Medina Complaint”). The Medina Complaint purports to be asserted on behalf of a class of persons who purchased Clovis stock between May 20, 2014 and November 13, 2015. On November 20, 2015, a third complaint was filed by John Moran in the United States District Court for the Northern District of California (the “Moran Complaint”). The Moran Complaint contains similar allegations to those asserted in the Kimbro and Medina Complaints and purports to be asserted on behalf of a plaintiff class who purchased Clovis stock between October 31, 2013 and November 13, 2015. On December 14, 2015, Ralph P. Rocco, a fourth purported shareholder of Clovis, filed a complaint in the United States District Court for the District of Colorado (the “Rocco Complaint”). The Rocco Complaint contains similar allegations to those set forth in the previous complaints and purports to be asserted on behalf of a plaintiff class who purchased Clovis stock between October 31, 2013 and November 15, 2015. On January 19, 2016, a number of motions were filed in both the District of Colorado and the Northern District of California seeking to consolidate the shareholder class actions into one matter and for appointment of a lead plaintiff. All lead plaintiff movants other than M. Arkin (1999) LTD and Arkin Communications LTD (the “Arkin Plaintiffs”) subsequently filed notices of non-opposition to the Arkin Plaintiffs’ application. On February 2, 2016, the Arkin Plaintiffs filed a motion to transfer the Moran Complaint to the District of Colorado (the “Motion to Transfer”). Also on February 2, 2016, the defendants filed a statement in the Northern District of California supporting the consolidation of all actions in a single court, the District of Colorado. On February 3, 2016, the Northern District of California court denied without prejudice the lead plaintiff motions filed in that court pending a decision on the Motion to Transfer. On February 16, 2016, the defendants filed a memorandum in support of the Motion to Transfer, and plaintiff Moran filed a notice of non-opposition to the Motion to Transfer. On February 17, 2016, the Northern District of California court granted the Motion to Transfer. On February 18, 2016, the Medina court issued an opinion and order addressing the various motions for consolidation and appointment of lead plaintiff and lead counsel in the District of Colorado actions. By this ruling, the court consolidated the Medina, Kimbro and Rocco actions into a single proceeding. The court also appointed the Arkin Plaintiffs as the lead plaintiffs and Bernstein Litowitz Berger & Grossman as lead counsel for the putative class. On April 1, 2016, the Arkin Plaintiffs and the defendants filed a stipulated motion to set the schedule for the filing of a consolidated complaint in the Medina, Kimbro and Rocco actions (the “Consolidated Complaint”) and the responses thereto, including the defendants’ motion to dismiss the Consolidated Complaint (the “Motion to Dismiss”), and to stay discovery and related proceedings until the District of Colorado issues a decision on the Motion to Dismiss. The stipulated motion was entered by the District of Colorado on April 4, 2016. Subject to further agreed-upon extensions by the parties, the Arkin Plaintiffs filed a Consolidated Complaint on May 6, 2016. The Consolidated Complaint names as defendants the Company and certain of its current and former officers (the “Clovis Defendants”), certain underwriters (the “Underwriter Defendants”) for a Company follow-on offering conducted in July 2015 (the “July 2015 Offering”) and certain Company venture capital investors (the “Venture Capital Defendants”). The Consolidated Complaint alleges that defendants violated particular sections of the Securities Exchange Act of 1934 (the “Exchange Act”) and the Securities Act of 1933 (the “Securities Act”). The purported misrepresentations and omissions concern allegedly misleading statements about rociletinib. The putative class action is purportedly brought on behalf of investors who purchased the Company’s securities between May 31, 2014 and April 7, 2016 (with respect to the Exchange Act claims) and investors who purchased the Company’s securities pursuant or traceable to the July 2015 Offering (with respect to the Securities Act claims). The Consolidated Complaint seeks unspecified compensatory and recessionary damages. On May 23, 2016, the Medina, Kimbro, Rocco and Moran actions were consolidated for all purposes in a single proceeding in the District of Colorado. The Clovis Defendants, along with the Underwriter Defendants and the Venture Capital Defendants, filed a Motion to Dismiss on July 27, 2016, the Arkin Plaintiffs filed their opposition on September 23, 2016, and the defendants filed their replies on October 14, 2016. The Clovis Defendants intend to vigorously defend against the allegations contained in the Kimbro, Medina, Moran and Rocco Complaints, but there can be no assurance that the defense will be successful. On December 30, 2015, Jamie McCall, a purported shareholder of Clovis, filed a shareholder derivative complaint (the “McCall Complaint”) against certain officers and directors of Clovis in the Colorado District Court, County of Boulder. The McCall Complaint generally alleged that the defendants breached their fiduciary duties owed to Clovis by participating in misrepresentation of the Company’s business operations and prospects. The McCall Complaint also alleged claims for abuse of control, gross mismanagement and unjust enrichment. The McCall Complaint sought, among other things, an award of money damages, declaratory and injunctive relief concerning the alleged fiduciary breaches and other forms of equitable relief. On March 17, 2016, the plaintiff filed a notice of voluntary dismissal of the McCall Complaint and the action was terminated by the Court. On January 22, 2016, the Electrical Workers Local #357 Pension and Health & Welfare Trusts, a purported shareholder of Clovis, filed a purported class action complaint (the “Electrical Workers Complaint”) against Clovis and certain of its officers, directors, investors and underwriters in the Superior Court of the State of California, County of San Mateo. The Electrical Workers Complaint purports to be asserted on behalf of a class of persons who purchased stock in Clovis’ July 8, 2015 follow-on offering. The Electrical Workers Complaint generally alleges that the defendants violated the Securities Act because the offering documents for the July 8, 2015 follow-on offering contained allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib. The Electrical Workers Complaint seeks unspecified damages. On February 25, 2016, the defendants removed the case to the United States District Court for the Northern District of California and thereafter moved to transfer the case to the District of Colorado (“Motion to Transfer”). On March 2, 2016, the plaintiff filed a motion to remand the case to San Mateo County Superior Court (“Motion to Remand”). Following briefing on the Motion to Transfer and the Motion to Remand, the Northern District of California held a hearing on April 18, 2016 concerning the Motion to Remand, at the conclusion of which the court granted to the Motion to Remand. On May 5, 2016, the Northern District of California issued a written decision and order granting the Motion to Remand the case to the Superior Court, County of San Mateo and denying the Motion to Transfer as moot. While the case was pending in the United States District Court for the Northern District of California, the parties entered into a stipulation extending the defendants’ time to respond to the Electrical Workers Complaint for 30 days following the filing of an amended complaint by plaintiff or the designation by plaintiff of the Electrical Workers Complaint as the operative complaint. Following remand, Superior Court of the State of California, County of San Mateo so-ordered the stipulation on June 22, 2016. On June 30, 2016, the Electrical Workers Plaintiffs filed an amended Complaint (the “Amended Complaint”). The Amended Complaint names as defendants the Company and certain of its current and former officers and directors, certain underwriters for the July 2015 Offering and certain Company venture capital investors. The Amended Complaint purports to assert claims under the Securities Act based upon alleged misstatements in Clovis’ offering documents for the July 2015 Offering. The Amended Complaint includes new allegations about the Company’s rociletinib disclosures. The Amended Complaint seeks unspecified damages. Pursuant to a briefing schedule ordered by the court on July 28, 2016, defendants filed a motion to stay the Electrical Workers action pending resolution of the Medina, Kimbro, Moran, and Rocco actions in the District of Colorado (“Motion to Stay”), and a demurrer to the Amended Complaint, on August 15, 2016; plaintiffs filed their oppositions on August 31, 2016; and the defendants filed their reply briefs on September 15, 2016. On September 23, 2016, after hearing oral argument, the San Mateo Superior Court granted defendants’ motion to stay proceedings pending resolution of the related securities class action captioned Medina v. Clovis Oncology, Inc., et. al., No. 1:15-cv-2546 (the “Colorado Action”). Per the order to stay proceedings, the San Mateo Superior Court will defer issuing a ruling on defendants’ pending demurrer, and the parties’ first status report as to the progress of the Colorado Action is due on March 23, 2017. The Company intends to vigorously defend against the allegations contained in the Electrical Workers Amended Complaint, but there can be no assurance that the defense will be successful. On February 19, 2016, Maris Sanchez, a purported shareholder of Clovis, filed a shareholder derivative complaint (the “Sanchez Complaint”) against certain officers and directors of Clovis in the United States District Court for the District of Colorado. The Sanchez Complaint generally alleged that the defendants breached their fiduciary duties owed to Clovis by participating in misrepresentation of the Company’s business operations and prospects. The Sanchez Complaint also alleged claims for abuse of control and gross mismanagement. The Sanchez Complaint sought, among other things, an award of money damages. On March 11, 2016, the plaintiff filed a notice of voluntary dismissal of the Sanchez Complaint without prejudice. On March 14, 2016, the Sanchez action was terminated by the District of Colorado. We have received requests for information from governmental agencies relating to our regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. We are cooperating with the inquiries. We received a letter dated May 31, 2016 from an alleged owner of our common stock, which purports to set forth a demand for inspection of certain of our books and records pursuant to 8 Del. C. § 220 (the “Demand Letter”). The Demand Letter was purportedly made for the purpose of investigating alleged misconduct at the Company relating to rociletinib. On June 24, 2016, we submitted a response to the Demand Letter. We believe that the Demand Letter fails to establish an entitlement to any of the requested documents, but there can be no assurance about the likelihood of an adverse outcome.

XML 33 R21.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events On October 3, 2016, we entered into a Manufacturing Services Agreement (the “Agreement”) with Lonza Ltd (“Lonza”) for the long term manufacture and supply of the active pharmaceutical ingredient (“API”) for rucaparib. The terms and conditions of the Agreement are contingent upon the approval by the FDA of the initial NDA for rucaparib, unless triggered earlier by us. Clovis and Lonza are parties to a Development and Manufacturing Agreement, dated February 8, 2013, as amended, under which Lonza has supplied rucaparib API for clinical development. The Agreement provides that Lonza will be a non-exclusive manufacturer of the rucaparib API during the term of the Agreement, which expires on December 31, 2025, unless extended by mutual written consent of the parties. Under the Agreement, Lonza will construct, in an existing Lonza facility, a production train that will be exclusively dedicated to the manufacture of the rucaparib API. The dedicated production train will provide manufacturing capacity to meet our currently anticipated needs for commercial supply of rucaparib API. We are obligated to make scheduled capital program fee payments towards capital equipment and other costs associated with the construction of the dedicated production train and, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement. Pursuant to the terms of the Agreement, Lonza will manufacture and store an advanced intermediate to be used in the subsequent production of the rucaparib API. We will pay fixed fees on a per kilogram basis for quantities of the advanced intermediate and the rucaparib API ordered by us under the Agreement, subject to certain adjustments. Until the dedicated facility is completed and operationally qualified, Lonza will manufacture the rucaparib API in existing Lonza facilities at pricing established in the Agreement. Either party may terminate the Agreement due to a material breach of the Agreement by the other party, subject to prior written notice and a cure period. We may terminate the Agreement, subject to 90 days’ prior written notice, in the event rucaparib is withdrawn from the market for certain reasons. In the event of such a termination by us, or termination by Lonza due to material breach by us, we are obligated to compensate Lonza for any services rendered, or for which costs have been incurred by Lonza in anticipation of services to be provided to us, and to pay to Lonza the remaining amount of any capital program fees and quarterly fixed facility fees for the remainder of the term of the Agreement. In the event the Agreement is terminated by us due to material breach by Lonza, Lonza is obligated to repay all or a portion of the capital program fees previously paid by us.

XML 34 R22.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Presentation (Policies)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Basis of Presentation

Reclassifications

Use of Estimates

Liquidity

Recently Issued Accounting Standards

Cash, Cash Equivalents and Available-for-Sale Securities

Fair Value Measurements

The three levels of inputs that may be used to measure fair value include:

Level 1:		Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.

Level 2:		Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

Level 3:		Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets that are measured at fair value on a recurring basis. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired with the purchase of EOS is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. See Note 3 of our 2015 Form 10-K for further discussion of the unobservable inputs and valuation techniques related to the contingent purchase consideration liability.

Intangible Assets and Goodwill

Convertible Senior Notes

The debt issuance costs are presented as a deduction from convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the Notes.

Accumulated Other Comprehensive Income (Loss)

Share-Based Compensation

Lucitanib

Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations.

Net Loss Per Common Share

XML 35 R23.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):

	Balance		Level 1		Level 2		Level 3
September 30, 2016
Assets:
Money market	$	227,182	$	227,182	$	—	$	—
U.S. treasury securities		75,054		—		75,054		—
Total assets at fair value	$	302,236	$	227,182	$	75,054	$	—
Liabilities:
Contingent purchase consideration	$	—	$	—	$	—	$	—
Total liabilities at fair value	$	—	$	—	$	—	$	—
December 31, 2015
Assets:
Money market	$	251,037	$	251,037	$	—	$	—
U.S. treasury securities		249,832		—		249,832		—
Total assets at fair value	$	500,869	$	251,037	$	249,832	$	—
Liabilities:
Contingent purchase consideration	$	24,661	$	—	$	—	$	24,661
Total liabilities at fair value	$	24,661	$	—	$	—	$	24,661

Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs)

The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) (in thousands):

	For the Nine
	Months Ended
	September 30, 2016
Liabilities:
Balance at beginning of period	$	24,661
Change in fair value (a)		(24,936	)
Change in foreign currency gains and losses		275
Balance at end of period	$	—

(a)

XML 36 R24.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities (Tables)

9 Months Ended

Sep. 30, 2016

Available For Sale Securities [Abstract]

Summary of Available-for-Sale Securities

As of September 30, 2016, available-for-sale securities consisted of the following (in thousands):

			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	75,024	$	30	$	—	$	75,054

As of December 31, 2015, available-for-sale securities consisted of the following (in thousands):

			Gross		Gross			Aggregate
	Amortized		Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Value
U.S. treasury securities	$	250,215	$	—	$	(383	)	$	249,832

Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position

	Aggregate		Gross
	Fair		Unrealized
	Value		Losses
U.S. treasury securities	$	249,832	$	(383	)

Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity

As of September 30, 2016, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):

	Amortized		Fair
	Cost		Value
Due in one year or less	$	75,024	$	75,054
Total	$	75,024	$	75,054

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

XML 37 R25.htm IDEA: XBRL DOCUMENT

Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2016

Other Current Assets [Abstract]

Other Current Assets

Other current assets were comprised of the following (in thousands):

	September 30,		December 31,
	2016		2015
Receivable from partners	$	1,258	$	3,241
Prepaid expenses- other		2,613		1,023
Receivable - other		825		889
Prepaid insurance		406		1,231
Receivable from landlord		—		1,153
Other		92		199
Total	$	5,194	$	7,736

XML 38 R26.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill (Tables)

9 Months Ended

Sep. 30, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of IPR&D Intangible Assets and Goodwill

	September 30,			December 31,
	2016			2015
IPR&D intangible assets:
Balance at beginning of period	$	101,500		$	212,900
Impairment of intangible asset (a)		(104,517	)		(89,557	)
Change in foreign currency gains (losses)		3,017			(21,843	)
Balance at end of period	$	—		$	101,500

Goodwill:
Balance at beginning of period	$	59,327		$	66,055
Change in foreign currency gains (losses)		1,421			(6,728	)
Balance at end of period	$	60,748		$	59,327

(a)

XML 39 R27.htm IDEA: XBRL DOCUMENT

Other Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2016

Payables And Accruals [Abstract]

Other Accrued Expenses

Other accrued expenses were comprised of the following (in thousands):

	September 30,		December 31,
	2016		2015
Accrued personnel costs	$	10,345	$	8,250
Accrued interest payable		299		2,096
Accrued expenses - other		1,262		959
Total	$	11,906	$	11,305

XML 40 R28.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes (Tables)

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Schedule of Total Interest Expense Recognized Related to Notes

The following table sets forth total interest expense recognized related to the Notes during the three and nine months ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Contractual interest expense	$	1,797	$	1,797	$	5,390	$	5,371
Amortization of debt issuance costs		311		302		928		900
Total interest expense	$	2,108	$	2,099	$	6,318	$	6,271

XML 41 R29.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Component of Other Comprehensive Income (Loss)

The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):

							Total
	Foreign						Accumulated
	Currency			Unrealized			Other
	Translation			Gains			Comprehensive
	Adjustments			(Losses)			Income (Loss)
Balance December 31, 2014	$	(24,448	)	$	—		$	(24,448	)
Period change		(22,629	)		(383	)		(23,012	)
Balance December 31, 2015		(47,077	)		(383	)		(47,460	)
Period change		3,526			412			3,938
Income tax expense		(1,335	)		(153	)		(1,488	)
Balance September 30, 2016	$	(44,886	)	$	(124	)	$	(45,010	)

XML 42 R30.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-Based Compensation Expense Recognized in Accompanying Statements of Operations

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Research and development	$	7,039	$	9,039	$	20,962	$	19,798
General and administrative		2,164		3,367		8,782		9,660
Total share-based compensation expense	$	9,203	$	12,406	$	29,744	$	29,458

Summary of Stock Options Activity

The following table summarizes the activity relating to our options to purchase common stock for the nine months ended September 30, 2016:

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value (Thousands)
Outstanding at December 31, 2015		5,360,257		$	51.53
Granted		1,829,537			21.85
Exercised		(139,396	)		7.85
Forfeited		(1,309,127	)		54.27
Outstanding at September 30, 2016 (a)		5,741,271		$	42.51		7.4	$	52,392
Vested and expected to vest at September 30, 2016		5,351,476		$	42.80		7.2	$	48,604
Exercisable at September 30, 2016		2,954,077		$	43.14		5.8	$	27,713

(a)

Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award

The following table summarizes information about our stock options as of and for the three and nine months ended September 30, 2016 and 2015:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Weighted-average grant date fair value per share	$	17.09	$	56.22	$	16.07	$	52.98
Intrinsic value of options exercised	$	930,417	$	5,307,365	$	1,555,342	$	15,361,206
Cash received from stock option exercises	$	687,332	$	1,953,938	$	1,094,855	$	4,534,288

Summary of Activity Relating to Company's Unvested Restricted Stock Units

The following table summarizes the activity relating to our unvested RSUs for the nine months ended September 30, 2016:

	Number of Units			Weighted- Average Grant Date Fair Value
Unvested as of December 31, 2015		—		$	—
Granted		526,180			21.65
Vested (a)		(9,750	)		19.37
Forfeited		(33,245	)		19.24
Unvested as of September 30, 2016		483,185		$	21.86
Expected to vest after September 30, 2016		398,525		$	21.80

(a)

During the second quarter of 2016, we accelerated the vesting of RSUs for certain employees.

XML 43 R31.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share

	Three and Nine Months Ended September 30,
	2016		2015
Convertible senior notes		4,646		4,646
Common shares under options and awards		3,772		5,232
Total potential dilutive shares		8,418		9,878

XML 44 R32.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Presentation - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of operating segments	1

XML 45 R33.htm IDEA: XBRL DOCUMENT

EOS Acquisition - Additional Information (Detail)		3 Months Ended
EOS Acquisition - Additional Information (Detail)	Nov. 19, 2013 USD ($)	Jun. 30, 2016 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2015 USD ($)	Nov. 19, 2013 EUR (€)
Business Acquisition [Line Items]
Reduction in fair value of contingent purchase consideration liability		$ 25,500,000
Contingent purchase consideration			$ 0	$ 24,661,000
Ethical Oncology Science, S.p.A.
Business Acquisition [Line Items]
Business acquisition cash payments made on acquisition	$ 11,800,000
Future maximum contingent milestone payments	193,500,000
Reduction in fair value of contingent purchase consideration liability		$ 25,500,000
Contingent purchase consideration			$ 0	$ 24,700,000
Ethical Oncology Science, S.p.A. \| Regulatory and Sales Milestones
Business Acquisition [Line Items]
Future maximum contingent milestone payments	65,000,000				€ 115,000,000
Future minimum potential contingent milestone payments	0				€ 0
Ethical Oncology Science, S.p.A. \| Common Stock
Business Acquisition [Line Items]
Business acquisition, common stock issued at acquisition date	$ 173,700,000

XML 46 R34.htm IDEA: XBRL DOCUMENT

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	$ 302,236	$ 500,869
Contingent purchase consideration, fair value	0	24,661
Liabilities at fair value		24,661
Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	227,182	251,037
Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	75,054	249,832
Fair Value, Inputs, Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent purchase consideration, fair value		24,661
Liabilities at fair value		24,661
Money Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	227,182	251,037
Money Market \| Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	227,182	251,037
U.S. Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	75,054	249,832
U.S. Treasury Securities \| Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	$ 75,054	$ 249,832

XML 47 R35.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfers between level 1 and level 2, assets			$ 0
Transfers between level 2 and level 1, assets			0
Transfer of liabilities into level 3			0
Transfer of liabilities out of level 3			0
Impairment of intangible asset	$ 104,500,000	$ 89,600,000	104,517,000
Intangible assets		101,500,000		$ 101,500,000
Convertible Senior Unsecured Notes
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Convertible senior notes			287,500,000
Convertible Senior Unsecured Notes \| Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Convertible senior notes, fair value			273,800,000
In Process Research and Development
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Impairment of intangible asset	$ 104,500,000		104,517,000	89,557,000
Intangible assets		$ 101,500,000	$ 0	$ 101,500,000	$ 212,900,000

XML 48 R36.htm IDEA: XBRL DOCUMENT

Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Detail) - Fair Value, Inputs, Level 3 $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Fair value, liabilities measured on recurring basis, unobservable input reconciliation, calculation rollforward
Balance at beginning of period	$ 24,661
Change in fair value	(24,936)
Change in foreign currency gains and losses	275
Balance at end of period	$ 0

XML 49 R37.htm IDEA: XBRL DOCUMENT

Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Reduction in fair value of contingent purchase consideration liability	$ 25,500
Contingent purchase consideration		$ 0	$ 24,661

XML 50 R38.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities - Summary of Available-for-Sale Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 75,024
Aggregate Fair Value	75,054
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	75,024	$ 250,215
Gross Unrealized Gains	30
Gross Unrealized Losses		(383)
Aggregate Fair Value	$ 75,054	$ 249,832

XML 51 R39.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities - Additional Information (Detail)	Sep. 30, 2016 USD ($)
Investments Debt And Equity Securities [Abstract]
Available-for-sale securities, continuous unrealized loss position, less than 12 Months	$ 0

XML 52 R40.htm IDEA: XBRL DOCUMENT

Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2016
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Fair Value		$ 0
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Fair Value	$ 249,832,000
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Gross Unrealized Losses	$ (383,000)

XML 53 R41.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail) $ in Thousands	Sep. 30, 2016 USD ($)
Available For Sale Securities Debt Maturities [Abstract]
Amortized Cost, Due in one year or less	$ 75,024
Amortized Cost	75,024
Fair Value, Due in one year or less	75,054
Aggregate Fair Value	$ 75,054

XML 54 R42.htm IDEA: XBRL DOCUMENT

Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Other Current Assets [Abstract]
Receivable from partners	$ 1,258	$ 3,241
Prepaid expenses- other	2,613	1,023
Receivable - other	825	889
Prepaid insurance	406	1,231
Receivable from landlord		1,153
Other	92	199
Other current assets	$ 5,194	$ 7,736

XML 55 R43.htm IDEA: XBRL DOCUMENT

Summary of IPR&D Intangible Assets and Goodwill (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Sep. 30, 2016	Dec. 31, 2015
IPR&D intangible assets:
Balance at beginning of period			$ 101,500
Impairment of intangible asset	$ (104,500)	$ (89,600)	(104,517)
Balance at end of period		101,500		$ 101,500
Goodwill:
Balance at beginning of period			59,327
Balance at end of period		59,327	60,748	59,327
In Process Research and Development
IPR&D intangible assets:
Balance at beginning of period			101,500	212,900
Impairment of intangible asset	$ (104,500)		(104,517)	(89,557)
Change in foreign currency gains (losses)			3,017	(21,843)
Balance at end of period		101,500	0	101,500
Ethical Oncology Science, S.p.A.
Goodwill:
Balance at beginning of period			59,327	66,055
Change in foreign currency gains (losses)			1,421	(6,728)
Balance at end of period		$ 59,327	$ 60,748	$ 59,327

XML 56 R44.htm IDEA: XBRL DOCUMENT

Summary of IPR&D Intangible Assets and Goodwill (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Finite Lived Intangible Assets [Line Items]
Impairment of intangible asset	$ 104,500	$ 89,600	$ 104,517
Intangible assets		101,500		$ 101,500
In Process Research and Development
Finite Lived Intangible Assets [Line Items]
Impairment of intangible asset	$ 104,500		104,517	89,557
Intangible assets		$ 101,500	$ 0	$ 101,500	$ 212,900

XML 57 R45.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Finite Lived Intangible Assets [Line Items]
Income tax benefit	$ 227			$ 628	$ 33,467	$ 508
Deferred tax benefit					$ 33,320	$ 529
In Process Research and Development
Finite Lived Intangible Assets [Line Items]
Deferred tax benefit		$ 29,200
Ethical Oncology Science, S.p.A.
Finite Lived Intangible Assets [Line Items]
Income tax benefit			$ 3,600

XML 58 R46.htm IDEA: XBRL DOCUMENT

Other Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Accrued personnel costs	$ 10,345	$ 8,250
Accrued interest payable	299	2,096
Accrued expenses - other	1,262	959
Other accrued expenses	$ 11,906	$ 11,305

XML 59 R47.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes - Additional Information (Detail) $ / shares in Units, $ in Thousands		9 Months Ended
	Sep. 09, 2014 USD ($) TD $ / shares	Sep. 30, 2016 USD ($)	Dec. 31, 2015 USD ($)
Debt Instrument [Line Items]
Convertible senior notes, aggregate principal amount		$ 280,813	$ 279,885
Convertible Senior Unsecured Notes
Debt Instrument [Line Items]
Convertible senior notes, aggregate principal amount	$ 287,500
Convertible senior notes, interest rate	2.50%
Net proceeds from convertible senior notes	$ 278,300
Convertible senior notes, frequency of periodic payment		semi-annually
Convertible senior notes, maturity date		Sep. 15, 2021
Convertible senior notes, initial conversion price per share \| $ / shares	$ 61.88
Common stock initial conversion rate per $1,000 in principal amount	16.1616
Last reported sale price of common stock	150.00%
Debt instrument, conversion in effect for number of trading days \| TD	20
Debt instrument conversion, consecutive trading day period	30 days
Debt instrument redemption price percentage to principal amount	100.00%
Debt instrument redemption description		On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.
Debt instrument, redemption period start date		Sep. 15, 2018
Debt instrument, trading days preceding redemption notice, maximum		2 days
Debt instrument repurchase percentage		100.00%
Debt issuance costs	$ 9,200
Debt instrument term		7 years
Unamortized debt issuance costs		$ 6,700	$ 7,600
Convertible Senior Unsecured Notes \| Semi Annual Payment, First payment date
Debt Instrument [Line Items]
Interest payment date on senior notes		--03-15
Convertible Senior Unsecured Notes \| Semi Annual Payment, Second payment date
Debt Instrument [Line Items]
Interest payment date on senior notes		--09-15

XML 60 R48.htm IDEA: XBRL DOCUMENT

Schedule of Total Interest Expense Recognized Related to Notes (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Debt Disclosure [Abstract]
Contractual interest expense	$ 1,797	$ 1,797	$ 5,390	$ 5,371
Amortization of debt issuance costs	311	302	928	900
Total interest expense	$ 2,108	$ 2,099	$ 6,318	$ 6,271

XML 61 R49.htm IDEA: XBRL DOCUMENT

Component of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance			$ 300,650
Period change, net of tax	$ 40	$ 423	2,450	$ (17,038)	$ (23,012)
Period change, before tax			3,938
Income tax expense			(1,488)
Ending balance	57,038		57,038		300,650
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance			(47,077)	(24,448)	(24,448)
Period change, net of tax					(22,629)
Period change, before tax			3,526
Income tax expense			(1,335)
Ending balance	(44,886)		(44,886)		(47,077)
Unrealized Gains (Losses)
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance			(383)
Period change, net of tax					(383)
Period change, before tax			412
Income tax expense			(153)
Ending balance	(124)		(124)		(383)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance			(47,460)	$ (24,448)	(24,448)
Ending balance	$ (45,010)		$ (45,010)		$ (47,460)

XML 62 R50.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 9,203	$ 12,406	$ 29,744	$ 29,458
Research and development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	7,039	9,039	20,962	19,798
General and administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 2,164	$ 3,367	$ 8,782	$ 9,660

XML 63 R51.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense, tax benefit recognized	$ 0	$ 0	$ 0	$ 0
Pretax intrinsic value, closing stock price	$ 36.05		$ 36.05
Unrecognized stock-based compensation expense related to non-vested options	$ 83,700,000		$ 83,700,000
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense, weighted-average remaining vesting period			2 years 9 months 18 days
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense, weighted-average remaining vesting period			3 years 4 months 24 days
Unrecognized stock-based compensation expense related to unvested RSUs	$ 8,400,000		$ 8,400,000

XML 64 R52.htm IDEA: XBRL DOCUMENT

Summary of Stock Options Activity (Detail) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($) $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Beginning Balance, Number of Options Outstanding \| shares	5,360,257
Number of Options, Granted \| shares	1,829,537
Number of Options, Exercised \| shares	(139,396)
Number of Options, Forfeited \| shares	(1,309,127)
Ending Balance, Number of Options Outstanding \| shares	5,741,271
Number of Options, Vested and expected to vest at September 30, 2016 \| shares	5,351,476
Number of Options, Exercisable at September 30, 2016 \| shares	2,954,077
Beginning Balance, Weighted Average Exercise Price \| $ / shares	$ 51.53
Granted, Weighted Average Exercise Price \| $ / shares	21.85
Exercised, Weighted Average Exercise Price \| $ / shares	7.85
Forfeited, Weighted Average Exercise Price \| $ / shares	54.27
Ending Balance, Weighted Average Exercise Price \| $ / shares	42.51
Vested and expected to vest, Weighted Average Exercise Price \| $ / shares	42.80
Exercisable, Weighted Average Exercise Price \| $ / shares	$ 43.14
Outstanding, Weighted Average Remaining Contractual Term (Years)	7 years 4 months 24 days
Vested and expected to vest, Weighted Average Remaining Contractual Term (Years)	7 years 2 months 12 days
Exercisable, Weighted Average Remaining Contractual Term (Years)	5 years 9 months 18 days
Outstanding, Aggregate Intrinsic Value \| $	$ 52,392
Vested and expected to vest, Aggregate Intrinsic Value \| $	48,604
Exercisable, Aggregate Intrinsic Value \| $	$ 27,713

XML 65 R53.htm IDEA: XBRL DOCUMENT

Summary of Stock Options Activity (Parenthetical) (Detail) - shares	3 Months Ended	9 Months Ended
	Mar. 31, 2015	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Granted		1,829,537
Performance Shares \| Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Granted	42,500

XML 66 R54.htm IDEA: XBRL DOCUMENT

Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted-average grant date fair value per share	$ 17.09	$ 56.22	$ 16.07	$ 52.98
Intrinsic value of options exercised	$ 930,417	$ 5,307,365	$ 1,555,342	$ 15,361,206
Cash received from stock option exercises	$ 687,332	$ 1,953,938	$ 1,094,855	$ 4,534,288

XML 67 R55.htm IDEA: XBRL DOCUMENT

Summary of Activity Relating to Company's Unvested Restricted Stock Units (Detail) - Restricted Stock Units (RSUs)	9 Months Ended
	Sep. 30, 2016 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning Balance, Number of Units Outstanding \| shares	0
Number of Units, Granted \| shares	526,180
Number of Units, Vested \| shares	(9,750)
Number of Units, Forfeited \| shares	(33,245)
Ending Balance, Number of Units Outstanding \| shares	483,185
Number of Units, Expected to vest after September 2016 \| shares	398,525
Weighted Average Grant Date Fair Value, Beginning Balance \| $ / shares	$ 0
Weighted Average Grant Date Fair Value, Granted \| $ / shares	21.65
Weighted Average Grant Date Fair Value, Vested \| $ / shares	19.37
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	19.24
Weighted Average Grant Date Fair Value, Ending Balance \| $ / shares	21.86
Weighted Average Grant Date Fair Value, Expected To Vest After September 2016 \| $ / shares	$ 21.80

XML 68 R56.htm IDEA: XBRL DOCUMENT

License Agreements - Additional Information (Detail) $ in Thousands	1 Months Ended					3 Months Ended				9 Months Ended
	Apr. 30, 2014 USD ($)	Sep. 30, 2012 EUR (€)	Jun. 30, 2011 USD ($)	May 31, 2010 USD ($)	Oct. 31, 2008	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Mar. 31, 2014 USD ($)	Mar. 31, 2012 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Acquired in process research and development costs						$ 500	$ 12,000			$ 800	$ 12,000
Development cost receivable						1,258				1,258		$ 3,241
Research and development						54,338	76,138			196,675	193,256
License Agreements Lucitanib
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment \| €		€ 45,000,000
Sublicense agreement consideration								$ 13,600
Additional payments receivable on milestone achievements \| €		90,000,000
Additional payments receivable on attaining the sales target \| €		250,000,000
Initial global development costs reimbursable \| €		€ 80,000,000
Development cost receivable						1,300				1,300		$ 3,200
Research and development						1,300	3,800			7,400	11,700
Reduction in research and development expense for reimbursable development costs due from Servier						$ 1,300	3,800			7,700	$ 10,400
License Agreements Licensor Pfizer \| Rucaparib
Research And Development Arrangement Contract To Perform For Others [Line Items]
Acquired in process research and development costs	$ 400									500
License Agreements Licensor Celgene Avilomics Research Inc \| Name of drug product in licensed by the entity Rociletinib
Research And Development Arrangement Contract To Perform For Others [Line Items]
Sales milestone payments										120,000
License Agreement Terms \| License Agreements Licensor Pfizer \| Rucaparib
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment			$ 7,000
Future expected development, regulatory and sales milestone payments										264,500
License Agreement Terms \| License Agreements Licensor Pfizer \| Rucaparib \| First approval of NDA by FDA
Research And Development Arrangement Contract To Perform For Others [Line Items]
Future expected development, regulatory and sales milestone payments										21,250
License Agreement Terms \| Advenchen Laboratories LLC \| License Agreements Lucitanib
Research And Development Arrangement Contract To Perform For Others [Line Items]
Acquired in process research and development costs								3,400
Percentage of Non-Royalty Consideration Payable on Sublicense Agreements					25.00%
License Agreement Terms \| License Agreements Licensor Celgene Avilomics Research Inc \| Name of drug product in licensed by the entity Rociletinib
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment				$ 2,000
Future expected regulatory and development payment										$ 98,000
License Agreement Terms \| License Agreements Licensor Celgene Avilomics Research Inc \| Name of drug product in licensed by the entity Rociletinib \| Regulatory Milestone Payment
Research And Development Arrangement Contract To Perform For Others [Line Items]
Acquired in process research and development costs							$ 12,000	$ 5,000	$ 4,000

XML 69 R57.htm IDEA: XBRL DOCUMENT

Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	8,418	9,878	8,418	9,878
Convertible senior notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	4,646	4,646	4,646	4,646
Common shares under options and awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	3,772	5,232	3,772	5,232

XML 70 R58.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - USD ($)		1 Months Ended
	Jun. 22, 2016	Feb. 28, 2013	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Purchase commitment			$ 48,500,000
Contractual agreement quarterly forecasts required period		24 months
Contractual agreement obligated forecast period		12 months
Defendants’ time to respond to electrical workers complaint	30 days

XML 71 R59.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - Subsequent Event - Lonza Ltd	Oct. 03, 2016
Subsequent Event [Line Items]
Manufacturing services agreement expiration date	Dec. 31, 2025
Manufacturing services agreement written notice period prior to termination	90 days

EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 113 244 1 false 35 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Statements of Operations Sheet http://www.clovisoncology.com/20160930/taxonomy/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 2 false false R3.htm 100020 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.clovisoncology.com/20160930/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 3 false false R4.htm 100030 - Statement - Consolidated Balance Sheets Sheet http://www.clovisoncology.com/20160930/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 4 false false R5.htm 100040 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Cash Flows Sheet http://www.clovisoncology.com/20160930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Nature of Business and Basis of Presentation Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation Nature of Business and Basis of Presentation Notes 7 false false R8.htm 100070 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - EOS Acquisition Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureEOSAcquisition EOS Acquisition Notes 9 false false R10.htm 100090 - Disclosure - Financial Instruments and Fair Value Measurements Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurements Financial Instruments and Fair Value Measurements Notes 10 false false R11.htm 100100 - Disclosure - Available-for-Sale Securities Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureAvailableForSaleSecurities Available-for-Sale Securities Notes 11 false false R12.htm 100110 - Disclosure - Other Current Assets Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureOtherCurrentAssets Other Current Assets Notes 12 false false R13.htm 100120 - Disclosure - Intangible Assets and Goodwill Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 13 false false R14.htm 100130 - Disclosure - Other Accrued Expenses Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureOtherAccruedExpenses Other Accrued Expenses Notes 14 false false R15.htm 100140 - Disclosure - Convertible Senior Notes Notes http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureConvertibleSeniorNotes Convertible Senior Notes Notes 15 false false R16.htm 100150 - Disclosure - Stockholders' Equity Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 100160 - Disclosure - Share-Based Compensation Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureShareBasedCompensation Share-Based Compensation Notes 17 false false R18.htm 100170 - Disclosure - License Agreements Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureLicenseAgreements License Agreements Notes 18 false false R19.htm 100180 - Disclosure - Net Loss Per Common Share Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureNetLossPerCommonShare Net Loss Per Common Share Notes 19 false false R20.htm 100190 - Disclosure - Commitments and Contingencies Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 100200 - Disclosure - Subsequent Events Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 21 false false R22.htm 100210 - Disclosure - Nature of Business and Basis of Presentation (Policies) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationPolicies Nature of Business and Basis of Presentation (Policies) Policies http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 100220 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables Financial Instruments and Fair Value Measurements (Tables) Tables http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurements 23 false false R24.htm 100230 - Disclosure - Available-for-Sale Securities (Tables) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureAvailableForSaleSecuritiesTables Available-for-Sale Securities (Tables) Tables http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureAvailableForSaleSecurities 24 false false R25.htm 100240 - Disclosure - Other Current Assets (Tables) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureOtherCurrentAssetsTables Other Current Assets (Tables) Tables http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureOtherCurrentAssets 25 false false R26.htm 100250 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureIntangibleAssetsAndGoodwill 26 false false R27.htm 100260 - Disclosure - Other Accrued Expenses (Tables) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureOtherAccruedExpensesTables Other Accrued Expenses (Tables) Tables http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureOtherAccruedExpenses 27 false false R28.htm 100270 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureConvertibleSeniorNotesTables Convertible Senior Notes (Tables) Tables http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureConvertibleSeniorNotes 28 false false R29.htm 100280 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureStockholdersEquity 29 false false R30.htm 100290 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureShareBasedCompensation 30 false false R31.htm 100300 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureNetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureNetLossPerCommonShare 31 false false R32.htm 100310 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail Nature of Business and Basis of Presentation - Additional Information (Detail) Details 32 false false R33.htm 100320 - Disclosure - EOS Acquisition - Additional Information (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureEOSAcquisitionAdditionalInformationDetail EOS Acquisition - Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 34 false false R35.htm 100340 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail Financial Instruments and Fair Value Measurements - Additional Information (Detail) Details 35 false false R36.htm 100350 - Disclosure - Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureRollForwardOfFairValueOfLevel3InstrumentsSignificantUnobservableInputsDetail Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Detail) Details 36 false false R37.htm 100360 - Disclosure - Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Parenthetical) (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureRollForwardOfFairValueOfLevel3InstrumentsSignificantUnobservableInputsParentheticalDetail Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Parenthetical) (Detail) Details 37 false false R38.htm 100370 - Disclosure - Available-for-Sale Securities - Summary of Available-for-Sale Securities (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetail Available-for-Sale Securities - Summary of Available-for-Sale Securities (Detail) Details 38 false false R39.htm 100380 - Disclosure - Available-for-Sale Securities - Additional Information (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureAvailableForSaleSecuritiesAdditionalInformationDetail Available-for-Sale Securities - Additional Information (Detail) Details 39 false false R40.htm 100390 - Disclosure - Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureSummaryOfFairValueAndGrossUnrealizedLossesOfAvailableForSaleSecuritiesInContinuousUnrealizedLossPositionDetail Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Detail) Details 40 false false R41.htm 100400 - Disclosure - Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail) Details 41 false false R42.htm 100410 - Disclosure - Other Current Assets (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureOtherCurrentAssetsDetail Other Current Assets (Detail) Details http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureOtherCurrentAssetsTables 42 false false R43.htm 100420 - Disclosure - Summary of IPR&D Intangible Assets and Goodwill (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureSummaryOfIPRDIntangibleAssetsAndGoodwillDetail Summary of IPR&D Intangible Assets and Goodwill (Detail) Details 43 false false R44.htm 100430 - Disclosure - Summary of IPR&D Intangible Assets and Goodwill (Parenthetical) (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureSummaryOfIPRDIntangibleAssetsAndGoodwillParentheticalDetail Summary of IPR&D Intangible Assets and Goodwill (Parenthetical) (Detail) Details 44 false false R45.htm 100440 - Disclosure - Intangible Assets and Goodwill - Additional Information (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetail Intangible Assets and Goodwill - Additional Information (Detail) Details 45 false false R46.htm 100450 - Disclosure - Other Accrued Expenses (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureOtherAccruedExpensesDetail Other Accrued Expenses (Detail) Details http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureOtherAccruedExpensesTables 46 false false R47.htm 100460 - Disclosure - Convertible Senior Notes - Additional Information (Detail) Notes http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetail Convertible Senior Notes - Additional Information (Detail) Details 47 false false R48.htm 100470 - Disclosure - Schedule of Total Interest Expense Recognized Related to Notes (Detail) Notes http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetail Schedule of Total Interest Expense Recognized Related to Notes (Detail) Details 48 false false R49.htm 100480 - Disclosure - Component of Other Comprehensive Income (Loss) (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureComponentOfOtherComprehensiveIncomeLossDetail Component of Other Comprehensive Income (Loss) (Detail) Details 49 false false R50.htm 100490 - Disclosure - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureShareBasedCompensationExpenseRecognizedInAccompanyingStatementsOfOperationsDetail Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) Details 50 false false R51.htm 100500 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 51 false false R52.htm 100510 - Disclosure - Summary of Stock Options Activity (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureSummaryOfStockOptionsActivityDetail Summary of Stock Options Activity (Detail) Details 52 false false R53.htm 100520 - Disclosure - Summary of Stock Options Activity (Parenthetical) (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureSummaryOfStockOptionsActivityParentheticalDetail Summary of Stock Options Activity (Parenthetical) (Detail) Details 53 false false R54.htm 100530 - Disclosure - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetail Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) Details 54 false false R55.htm 100540 - Disclosure - Summary of Activity Relating to Company's Unvested Restricted Stock Units (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureSummaryOfActivityRelatingToCompanySUnvestedRestrictedStockUnitsDetail Summary of Activity Relating to Company's Unvested Restricted Stock Units (Detail) Details 55 false false R56.htm 100550 - Disclosure - License Agreements - Additional Information (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetail License Agreements - Additional Information (Detail) Details 56 false false R57.htm 100560 - Disclosure - Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureSharesOutstandingExcludedFromCalculationOfDilutedNetLossPerShareDetail Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share (Detail) Details 57 false false R58.htm 100570 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 58 false false R59.htm 100580 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.clovisoncology.com/20160930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 59 false false All Reports Book All Reports clvs-20160930.xml clvs-20160930.xsd clvs-20160930_cal.xml clvs-20160930_def.xml clvs-20160930_lab.xml clvs-20160930_pre.xml true true ZIP 78 0001564590-16-027567-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-16-027567-xbrl.zip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